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A B S T R A C T
Background
Autogenic drainage is an airway clearance technique that was developed by Jean Chevaillier in 1967. The technique is characterised by
breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. Secretions are cleared independently
by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation. The technique
requires training, concentration and effort from the individual. It is important to systematically review the evidence demonstrating that
autogenic drainage is an effective intervention for people with cystic fibrosis.
Objectives
To compare the clinical effectiveness of autogenic drainage in people with cystic fibrosis with other physiotherapy airway clearance
techniques.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals
and conference abstract books. We also searched the reference lists of relevant articles and reviews, as well as two trials registers (31
August 2017).
Dtae of most recent search of the Cochrane Cystic Fibrosis Trials Register: 25 September 2017.
Selection criteria
We identified randomised and quasi-randomised controlled studies comparing autogenic drainage to another airway clearance technique
or no therapy in people with cystic fibrosis for at least two treatment sessions.
Data collection and analysis
Data extraction and assessments of risk of bias were independently performed by two authors. The authors assessed the quality of
the evidence using the GRADE system. The authors contacted two investigators for further information pertinent to their published
studies.
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Main results
Searches retrieved 35 references to 21 individual studies, of which seven (n = 208) were eligible for inclusion. One study was of parallel
design with the remaining six being cross-over in design; participant numbers ranged from 17 to 75. The total study duration varied
between four days and two years. The age of participants ranged between seven and 63 years with a wide range of disease severity
reported. Six studies enrolled participants who were clinically stable, whilst participants in one study had been hospitalised with an
infective exacerbation. All studies compared autogenic drainage to one (or more) other recognised airway clearance technique. Exercise
is commonly used as an alternative therapy by people with cystic fibrosis; however, there were no studies identified comparing exercise
with autogenic drainage.
The quality of the evidence was generally low or very low. The main reasons for downgrading the level of evidence were the frequent
use of a cross-over design, outcome reporting bias and the inability to blind participants.
The review’s primary outcome, forced expiratory volume in one second, was the most common outcome measured and was reported
by all seven studies; only three studies reported on quality of life (also a primary outcome of the review). One study reported on adverse
events and described a decrease in oxygen saturation levels whilst performing active cycle of breathing techniques, but not with autogenic
drainage. Six of the seven included studies measured forced vital capacity and three of the studies used mid peak expiratory flow (per
cent predicted) as an outcome. Six studies reported sputum weight. Less commonly used outcomes included oxygen saturation levels,
personal preference, hospital admissions or intravenous antibiotics. There were no statistically significant differences found between
any of the techniques used with respect to the outcomes measured except when autogenic drainage was described as being the preferred
technique of the participants in one study over postural drainage and percussion.
Authors’ conclusions
Autogenic drainage is a challenging technique that requires commitment from the individual. As such, this interventionmerits systematic
review to ensure its effectiveness for people with cystic fibrosis. From the studies assessed, autogenic drainage was not found to be
superior to any other form of airway clearance technique. Larger studies are required to better evaluate autogenic drainage in comparison
to other airway clearance techniques in view of the relatively small number of participants in this review and the complex study designs.
The studies recruited a range of participants and were not powered to assess non-inferiority. The varied length and design of the studies
made the analysis of pooled data challenging.
P L A I N L A N G U A G E S U M M A R Y
The autogenic drainage breathing technique for helping people with cystic fibrosis to clear mucus from their airways
Background
Cystic fibrosis affects the lungs by producing thick mucus lining the airways. This can lead to infection and inflammation causing lung
damage. Physiotherapy can help to keep the airways clear of mucus and there are many methods used to do this, including breathing
techniques, manual techniques and mechanical devices. Autogenic drainage is a very controlled technique of breathing which uses
different depths and speeds of exhaled breath to move mucus up the airways resulting in a spontaneous or voluntary cough. It can be
used without help, but requires training, concentration and effort. We looked at the effect of using autogenic drainage on lung function
measurements and quality of life in people with cystic fibrosis, to discover whether using autogenic drainage was better or worse than
other existing physiotherapy techniques for clearing the lungs.
Search date
The evidence is current to: 25 September 2017.
Study characteristics
We searched the literature for studies comparing at least two sessions of autogenic drainage with other breathing techniques and devices
which help to clear the lungs of mucus. We included seven studies in the review involving 208 people with cystic fibrosis, aged between
seven and 63 years of age. People were selected for one physiotherapy treatment or the other randomly. The number of people in the
studies ranged from 17 to 75, and had a wide range of disease severity. The studies lasted from four days to two years in total.
Key results
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We did not find any clear evidence that autogenic drainage was better than the other techniques for lung function or quality of life in
either the short-term or long-term studies. This was also true for our other outcome measures such as hospital admissions, additional
antibiotic treatment, exercise tolerance and oxygen saturation, but in one study autogenic drainage was the preferred technique compared
to postural drainage and percussion. Exercise was identified as a comparator for airway clearance by the authors of this review but no
included studies used it in this way, even though it is often used as an alternative therapy by people with cystic fibrosis.
Quality of the evidence
Overall, the quality of the evidence from the studies was judged to be mainly low or very low. The main problems for this being the
small numbers of participants in each study, the unclear reporting of results in the studies and the study design used. In one study, which
was classed as having a high risk of bias due to incomplete results, those taking part had to change physiotherapy technique halfway
through the study and there were many who dropped out and did not comply with the postural drainage and percussion treatment
arm. Five of the seven studies used research staff to assess results who did not know which technique each person was using and this
improved the quality of the evidence and reduced any bias.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
AD compared with conventional physiotherapy for CF
Patient or population: adults and children with CF
Settings: outpat ients
Intervention: AD
Comparison: convent ional physiotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional physio-
therapy
AD
FEV % predicted
(change from baseline)
Follow-up: up to 12
months
The mean change in
FEV (% predicted)
was 2.09% in the con-
vent ional physiother-
apy group (also see
comment)
The mean change in
FEV (%predicted) was
1.12% lower (2.64%
lower to 0.40% higher)
in the AD group (also
see comment)
NA 54 participants
(2 studies)
⊕©©©
very low1,2
Data available for anal-
ysis for 31 part icipants
f rom the f irst treatment
period of one study
No signif icant dif f er-
ence in FEV between
groups in the second
study
QoL (Likert scale 0 -
10)
Follow-up: up to 12
months
See comment. NA 54 participants
(2 studies)
⊕©©©
very low1,2,3
Part icipants sub-
ject ively reported AD to
be superior to conven-
t ional physiotherapy in
terms of comfort , level
of control and degree
of interrupt ion in their
daily lif e
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Participant preference
Follow-up: 12 months
See comment. See comment. NA 36 participants
(1 study)
⊕©©©
very low1,2,3
All part icipants re-
ported a preference for
autogenic drainage and
many refused to go
back to convent ional
physiotherapy
Exercise tolerance Not reported. NA NA NA
Adverse events Not reported. NA NA NA
Number of admissions
to hospital
Follow-up: 12 months
There were 16 hospi-
talisat ions in the con-
vent ional physiother-
apy group
There were 13 hospitali-
sat ions in the AD group.
NA 36 participants
(1 study)
⊕©©©
very low1,2
Un-
clear which treatment
period of the cross-over
study these hospitali-
sat ions occurred in, so
data not analysed
Need for extra treat-
ment
See comment. NA 36 participants
(1 study)
⊕©©©
very low1,2
No part icipants re-
ceived home intra-
venous ant ibiot ic treat-
ment
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in one second; NA: not applicable; QoL: quality of lif e.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison.
2. Downgraded twice due to serious risk of bias; incomplete outcome data and select ively reported results.
3. Downgraded once due to applicability; outcomes are recorded subject ively.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetic condition which is inherited in
an autosomal recessive manner (two carrier parents have a one in
four chance of a child with CF). It is more prevalent in Northern
European populations (incidence of around one in 3000 births
(Farrell 2008)) but less prevalent in populations from outside of
Europe (Farrell 2008). The affected gene codes for the production
of a protein that is involved in the movement of salt across cell
walls. Infants born with CF often have minimal disease expression
in their early weeks of life, but the abnormal salt transport predis-
poses them to a number of different problems; most commonly
salt loss through abnormal sweat production, poor absorption of
food through pancreatic dysfunction and airway infection and in-
flammation through dysfunction of the airway clearance mecha-
nism that normally protects the lungs (Tiddens 2010).
Abnormal salt transport impacts on the production of airway sur-
face liquid, which potentially disturbs the ability of the cilia to
clear the airways (Boucher 2004). This is an important physiolog-
ical process, called themucociliary escalator, for protecting the air-
ways. Disruption of this process makes the airways vulnerable to
the unusual infections that characterise CF lung disease. Once es-
tablished, airway infection and inflammation exacerbate the poor
airway clearance. Together with increased production of airway
mucus, this leads to a cycle of chronic infection, inflammation and
airway damage (Cantin 2015; Konstan 1997). It is the impact of
the CF defect on the airways that is the most significant cause of
morbidity and ultimately early death for people with CF (Tiddens
2010).
Description of the intervention
There is evidence from systematic reviews, including Cochrane
Reviews, that exercise and airway clearance are important, even
during early stages of the condition, for maintaining respiratory
health (Flume 2009). With more established airway infection, air-
way clearance techniques are critical to maintaining respiratory
function and preventing the deterioration associated with infec-
tion and inflammation.
There are a number of different airway clearance techniques (in-
cluding exercise) that exist and these have been evaluated by other
Cochrane Reviews (Main 2005; McIlwaine 2015; Mckoy 2016;
Morrison 2017; Radtke 2015; Warnock 2015). The most tradi-
tional technique involves percussion with the individual in several
different positions to loosen secretions. Newer strategies involve
the use of devices, ranging from simple and cheap airway oscil-
lating devices (AOD), through devices generating positive expira-
tory pressure (PEP) or Hi-PEP to high frequency chest wall os-
cillation (HFCWO) devices which have significant cost implica-
tions. Other techniques focus more on the individual appreciat-
ing and controlling their breathing pattern and using this to aug-
ment airway clearance. These techniques include the active cycle
of breathing (ACBT) and autogenic drainage (AD), the subject of
this review. Exercise is commonly used as an alternative therapy
by people with CF.
Jean Chevaillier developed AD as an airway clearance technique
in 1967 and AD is characterised by the individual with CF un-
derstanding and controlling their breathing (Chevaillier 1984).
Secretions are cleared by adjusting the rate, depth and location
of respiration in a sequence of controlled breathing techniques.
The mechanism of mucus clearance rests on two different systems,
the effect of the ciliary clearance and the effect of shearing forces
induced by the airflow. To create the necessary shearing forces to
clear the bronchi from secretions, it is essential to modulate the
inspiratory and expiratory airflow. In order to do this, the indi-
vidual inspires with a deeper than normal breath, described by
Chevaillier as the functional tidal volume (1.5 to 2 times the size
of normal tidal volume), and exhales in a gentle but active way
as a sigh. Individuals breathe in with inspiratory pauses through
an open glottis, allowing more time for obstructed areas of the
lung to fill equally and air to move behind secretions. These secre-
tions are mobilised from the periphery of the lungs to the mouth
by adjusting the lung volume at which the individual is perform-
ing the AD-style breathing in three distinct phases. In the first
phase, known as the ’un-sticking phase’, repeated low-lung vol-
ume breaths are used within the expiratory reserve volume, i.e.
the individual will be instructed to breathe out as far as possible
and then to breathe the functional tidal volume. To localize the
secretions the three feedback signals (auditive, tactile and propri-
oceptive) are used, which informs the individual to move to the
next phase. In the second phase (collective phase) a mid-volume
level of breathing is used, progressing into the inspiratory reserve
and secretions are mobilised ready to be expectorated in the third
(evacuation) phase using a huff (forced expiration technique) or
controlled cough. The aim of breathing in this way is to achieve
the highest possible expiratory air flow simultaneously in differ-
ent generations of the bronchi, keeping bronchial resistance low,
and avoiding bronchospasm and dynamic airway collapse. Under
these circumstances, the speed of air flow may mobilise secretions
by shearing them from the bronchial walls and transporting them
from the peripheral to the central airways (IPG/CF 2009). The
use of AD prevents airway collapse during forced expiratory ma-
neuvers and it may consume less energy compared to other airway
clearance techniques (Agostini 2007). In addition to the clinical
benefit and improvement in forced expiratory volume in one sec-
ond (FEV ) and forced vital capacity (FVC), a recent study in
adults with CF has shown that AD improved inspiratory resistance
in all airways except the distal small airways (Prevotat 2017).
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How the intervention might work
The rationale behind airway clearance is simple, that removing in-
fected secretions from the airway will improve ventilatory capacity
and reduce direct inflammatory effects on the airway epithelia.
There is convincing evidence that such a strategy is important and
effective for people with chronic airway infection, but there is a
less robust evidence base for those who do not have chronic airway
infection and are not usually productive of sputum (McIllwaine
2014).
Why it is important to do this review
All airway clearance techniques are time-consuming and require
effort and commitment from the individual (Rand 2013). Some
techniques have significant cost implications (Morrison 2017).
While AD requires training and support from therapists, it is a
popular technique with many people with CF. It allows indepen-
dence from carers, is recognised to be effective in the modulation
of airflow and capable of augmenting the physiological process of
the body’s mucociliary escalator.
It is important that interventions which have cost implications
and are a burden on the time of people with CF are systematically
reviewed for evidence of efficacy.
O B J E C T I V E S
To compare the clinical effectiveness of AD in people with CF
with other physiotherapy airway clearance techniques.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs.
Types of participants
Children and adults with CF with a diagnosis based on sweat
testing or genetic testing or any combination of these.
Types of interventions
This review will compare AD to all other recognised airway clear-
ance techniques either as a single technique or in combination
with other techniques for at least two treatment episodes. In a post
hoc change, it was felt that it would be difficult to assess AD in
a single treatment episode, therefore such short studies were not
included in this review.
Autogenic drainage (AD)
This airway clearance technique was developed by JeanChevaillier
in 1967 and is characterised by breathing control using expira-
tory airflow to mobilise secretions from smaller to larger airways.
Secretions are cleared independently by adjusting the depth and
speed of respiration in a sequence of controlled breathing tech-
niques during exhalation (IPG/CF 2009).
Conventional physiotherapy
Postural drainage and percussion (PD&P) was first introduced for
the treatment of CF in the 1950s. Postural drainage (PD) has con-
sisted of placing the individual in a position which allows grav-
ity to assist in draining mucus from the periphery of the lungs
centrally. In more recent years modified postural drainage is com-
monly used, which involves positioning without the use of head-
down tilt (Button 2016). Percussion and vibration manual tech-
niques are used as an adjunct to PD and are directed over the chest
wall. Deep breathing, huffing and directed coughing complete the
treatment (Main 2005).
Active cycle of breathing technique (ACBT)
This technique combines breathing control, thoracic expansion
exercises and forced expiratory techniques (FET) (Pryor 1999).
Breathing control involves relaxed tidal volume breathing using
diaphragmatic control, whereas thoracic expansion exercises focus
on active inspiration to increase lung volumes. After one or more
cycles of breathing control and thoracic expansion exercises, FET
is encouraged from a high-lung volume. The regimen is flexible
and can be adapted to suit the individual (Button 2016). Chest
wall manipulation and postural drainage may also be included
along with this cycle.
Exercise
Physical exercise that increases minute ventilation leads to the
mobilization of pulmonary secretions and enhances airway clear-
ance. Physiological effects of exercise include reduced mechanical
impedance of sputum, enhanced expiratory flow rates and induce-
ment of coughing (Button 2016; Dwyer 2011). Evidence from
both short- and long-term studies shows that exercise has a posi-
tive effect on lung function and well-being (Radtke 2015).
Positive expiratory pressure (PEP)
The PEP mask or mouthpiece contains a valve that increases resis-
tance to expiratory airflow. The individual repeats 10 to 15 breaths
through the flow resistor, creating positive pressures of 10 to 20
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cm H O in the airways The theoretical benefit of PEP therapy
lies in its ability to enhance and promote mucus clearance by one
or more mechanisms: by preventing small airway collapse through
stenting of the airways; or, by enhancing lung recruitment distal
to retained secretions using collateral ventilation (Andersen 1979;
Groth 1985); or, by temporarily increasing functional residual ca-
pacity (McIlwaine 2015).
High-pressure PEP (Hi-PEP)
The Hi-PEP mask physiotherapy employs forced expiratory ma-
noeuvres against the PEP mask’s expiratory resistor. An individual
performs PEP breathing for eight to 10 cycles using moderately
increased tidal breathing before inhaling to total lung capacity and
performing a forced expiratory manoeuvre against the stenosis.
Sustained expiratory pressures achieved usually range between 40
and 100 cm H O (Oberwaldner 1986).
Oscillatory devices
There are several devices available for augmenting airway clear-
ance.
Cornet®
The Cornet® is a horn-shaped plastic tube which houses a rubber
inner hose. Expiration through the Cornet® causes the hose to
flex, buckle and unbuckle, causing oscillating positive pressure
in the airways which fluctuates rapidly. The mouthpiece can be
adjusted to produce the optimal resistance and oscillation (Pryor
1999).
Flutter®
The Flutter VRP1 device comprises a mouthpiece, a plastic cone,
a steel ball and a perforated cover. During exhalation through the
device, the tracheobronchial tree undergoes internal vibrations,
together with repeated changes of the expiratory airflow against
the resistance (PEP component) and oscillations in endobronchial
pressure (oscillatory component). This facilitates the mobilisation
and loosening of secretions (Konstan 1994; Pryor 1999).
High frequency chest wall oscillations (HFCWO)
HFCWO delivers external compression pulses to the chest wall
through an inflatable vest connected to an air pulse generator.The
generator produces an alternating flow of air into, and out of,
the vest that rapidly compresses and releases the chest wall within
a range of selectable frequencies and pressures. The oscillatory
compression imparted to the chest wall has been reported to thin
viscous mucus, mobilise secretions and propel mucus to the major
airways (Warwick 1991).
Intrapulmonary percussive ventilation (IPV)
This technique utilizes high frequency oscillatory ventilation to
produce endotracheal percussion via the mouth using a device
called the Percussionator. Percussive bursts of high-flow respiratory
gas are delivered throughout the entire respiratory cycle at high
rates. These cause oscillatory airflow which vibrates the airway
walls to loosen and mobilize secretions towards the upper airways
and oral pharynx (Homnick 1995).
Acapella
TheAcapella combines the principles of high-frequency oscillation
and PEP by employing a counterweighted lever and magnet. Ex-
haled gas passes through a cone, which is intermittently occluded
by a plug attached to the lever, producing airflow oscillations. A
dial located at the distal end of the device adjusts the proximity
of the magnet and counterweighted plug, thereby adjusting the
frequency, amplitude, and mean pressure (Volsko 2003).
Quake® (Thayer Medical, Tucson, Arizona, USA)
This device produces airway oscillation during both inspiration
and expiration.The design consists of a manually turned outer
barrel which rotates around an inner barrel. Airflow occurs only
when vanes within the two barrels line up and is interrupted at
regular intervals as the user turns the handle. Percussion is achieved
as small bursts of air are inhaled and exhaled through the vanes of
the device (Okeson 2007).
Types of outcome measures
Primary outcomes
1. FEV
2. Quality of life (QoL) as measured by any of the scales
including:
i) Cystic Fibrosis Questionnaire-Revised version (CFQ-
R) (Quittner 2009)
ii) Cystic Fibrosis Quality of Life Questionnaire
(CFQoL) (Gee 2000)
iii) Quality of Well-being (QWB)
iv) Nottingham Health Profile (NHP)
v) any other validated QoL scale
Secondary outcomes
1. Participant preference
2. Exercise tolerance
i) six-minute walk test
ii) shuttle walk test
iii) cardiopulmonary exercise testing (CPET)
iv) any other validated exercise evaluation
3. Adverse effects (e.g. haemoptysis, bronchospasm,
desaturation)
4. Number of admissions to hospital
5. Need for extra treatment
6. Other pulmonary function measurements
i) lung clearance index (LCI) (post hoc change)
ii) FVC
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iii) forced mid-expiratory flow between 25% and 75% of
FVC (FEF25−75%)
7. Oxygen saturation
i) pulse oximeter
ii) arterial blood gas analysis
8. Sputum weight
9. Survival
Search methods for identification of studies
There was no restriction on language or publication status.
Electronic searches
We identified relevant studies from the Group’s Cystic Fibrosis
Trials Register by using the term: autogenic drainage.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books relevant conferences, including
three major cystic fibrosis conferences: the International Cystic
Fibrosis Conference; the EuropeanCystic Fibrosis Conference and
the North American Cystic Fibrosis Conference. For full details
of all searching activities for the register, please see the relevant
sections of the Cochrane Cystic Fibrosis and Genetic Disorders
Group website.
Date of last search of the CF Register: 25 September 2017.
We also searched two online trials registries:
• ClinicalTrials.gov (clinicaltrials.gov) using the key words
’autogenic drainage’ and ’forced expiratory techniques’, as well as
’autogenic drainage’ and ’cystic fibrosis’ (date of last search 21
September 2017);
• WHO ICTRP (http://apps.who.int/trialsearch/) using the
key words “autogenic drainage AND forced expiratory
techniques” as well as “autogenic drainage AND cystic fibrosis”
(date of last search 31 August 2017).
Searching other resources
We checked the reference lists from the identified studies for fur-
ther assessment. We also screened the references of all published
Cochrane Reviews related to this title.
Data collection and analysis
Selection of studies
Two authors (PM, PB) independently screened the results of the
searches for relevant articles based on the title and abstract. They
included the studies which either of them identified as relevant and
reviewed the full text of those studies. They screened the full text
articles to determine the eligibility of the study for inclusion in the
review. In case of any disagreement, they planned to consult the
third author (KWS), but there were no instances of disagreement.
For studies published in languages other than English, the authors
planned to seek translation.
Data extraction and management
The authors (PM, PB) independently extracted the data using
specifically formulated data extraction forms. The extracted data
included characteristics of the participants, information on the
study design (type of randomisation, type of allocation conceal-
ment, number of participants), aspects of the intervention (details
of intervention and control intervention, duration of interven-
tion, frequency of intervention, compliance with intervention, in-
tensity of intervention and details of multifaceted interventions),
outcome measures, adverse effects and dropouts.
The authors presented results separately for each comparison of
techniques, i.e. AD versus conventional physiotherapy, AD versus
ACBT, AD versus PEP, etc. We do not combine all oscillating de-
vices together, instead present separate comparisons for AD versus
Flutter® and AD versus Cornet®.
They compared the effect of treatment both in the short term
and long term. In a post hoc change, for short-term studies (up
to one month), the authors reported outcomes of up to seven
days, and from one to four weeks. Likewise, the outcome data for
longer-term studieswere reported as thosemeasured at onemonth,
threemonths, sixmonths, 12months and annually thereafter. The
authors also planned to consider any outcome data recorded at
other time periods. In a post hoc change, the authors felt that it
was difficult to assess the relevance of AD treatment after a single
treatment intervention, so did not included these extremely brief
studies in the review, setting instead a minimum requirement of
two treatment sessions for inclusion.
Assessment of risk of bias in included studies
The authors (PM, PB) independently assessed the risk of bias
from the included studies using the approach recommended
in theCochrane Handbook of Systematic Reviews of Interventions
(Higgins 2011). They planned to resolve any disagreements by
consensus, but this was not necessary. The authors assessed and
rated the following domains.
1. Generation of sequence
Low risk of bias: using a computerised random generator, random
number tables, coin tossing or any other valid method.
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High risk of bias: sequence generation and allocation done by in-
validmethods such as using odd or even date of birth, or allocation
by the judgement of the clinician.
Unclear risk of bias: insufficient information provided about the
sequence generation process.
2. Concealment of allocation sequence
Low risk of bias: allocation concealed so that neither the investiga-
tors or participants know group assignment at the time of study en-
try. Valid methods include central randomisation or serially num-
bered, opaque, sealed envelopes.
High risk of bias: the method of allocation is not concealed (e.g.
visible list of randomnumbers, unsealed or non-opaque envelopes)
leading to transparency in group assignments and thereby intro-
ducing selection bias.
Unclear risk of bias: insufficient information provided about the
concealment of allocation process.
3. Blinding of participants, personnel and outcome assessors
Note: we considered the risk of bias from blinding for the study
overall rather than per outcome.
Low risk of bias: either participants or some key study personnel
could not or were not blinded, but the outcome assessment was
blinded and the non-blinding of others is unlikely to introduce
bias.
High risk of bias: no blinding or incomplete blinding and the out-
come measurement is likely to be influenced by lack of blinding.
Unclear risk of bias: insufficient information or the study report
did not mention it.
4. Incomplete outcome data
Low risk of bias:missingdata have been includedusing appropriate
methods such as intention-to-treat analysis.
High risk of bias: authors did not include intention-to-treat anal-
ysis for missing data.
Unclear risk of bias: insufficient reporting of attrition or exclusions,
no reasons for missing data provided.
5. Selective outcome reporting
Low risk of bias: the published article(s) report(s) primary and
secondary outcomes that are of interest to the review in the pre-
specified way.
High risk of bias: pre-specified outcomes not reported.
Unclear risk of bias: insufficient information to permit judgement
of low or high risk.
6. Other potential threats to validity
Low risk of bias: the study appears to be free of other sources of
bias.
High risk of bias: evidence of other potential sources of bias, e.g.
there is bias pertaining to the study design (e.g. extreme baseline
imbalance).
Unclear risk of bias: insufficient information to assess whether any
important risk of bias exist.
Authors previously stated that they would not be allowed to assess
the risk of bias in studies in which they were involved, but no
such studies were relevant for this review. For studies published
in languages other than English, authors fluent in that language
would assess the risk of bias or the study would be translated; no
such studies were relevant.
Measures of treatment effect
Where possible, for continuous outcomes (FEV , QoL, exer-
cise tolerance, number of admissions to hospital, LCI, FVC,
FEF25−75%, pulse oximetry, arterial blood gas analysis and sputum
weight) using the same unit of measurement, the authors reported
the mean difference (MD) and 95% confidence intervals (CIs).
They reported the standardised mean difference (SMD) with 95%
CIs for continuous outcomes using different units of measure-
ment. For dichotomous outcomes (participant preference, adverse
effects, need for extra treatment and survival), the authors planned
to report risk ratio (RR) and 95%CIs, however, no such outcomes
have been analysed.
Unit of analysis issues
When combining the data from cross-over studies, the authors
planned to use the methods recommended by (Elbourne 2002). It
is common that the analysis and presentation of results from cross-
over studies are often not appropriate or clear, leading to limited
data being available for analysis (Nolan 2016). This was true for
most of the studies included in this review and since only limited
data were available, the authors used only the first-arm data from
the studies in order to avoid the carry-over effect (Curtin 2002).
As results were not presented from paired analyses for one study
(Pfleger 1992), we treated this cross-over study as if it was a parallel
study, which is a conservative approach as it does not take into
account within-patient correlation.
Cluster-randomised studies are not appropriate for this interven-
tion. Where we have included studies with multiple treatment
groups, each comparison is presented in a separate analysis.
Dealing with missing data
The review authors contacted the authors of included studies re-
garding all missing data. If the study authors had been unavailable
or the additional data were insufficient for analysis, the review au-
thors planned to include a narrative description of the study in the
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review. The review authors contacted two teams of investigators
and obtained additional data (McIlwaine 1991; Osman 2010).
Assessment of heterogeneity
For studies which investigated the effect of similar interventions
on similar participants and assessed similar outcomes (clinically
homogenous), the authors planned to pool the data in a meta-
analysis. However, it was not possible to combine data for any
outcome measure. If there had been heterogeneity, the authors
planned to assess this using the Chi² test and the I² statistic (with
CIs) (Higgins 2003). The authors planned to regard heterogeneity
as low if I² was less than 25%, moderate if I² was between 25%
and 50% and substantial if I² was over 50%.
Assessment of reporting biases
The review authors planned to use funnel plots to assess any re-
porting bias if there had been a sufficient number of studies in-
cluded (a minimum of 10 studies required for the assessment of
biases). Had there been asymmetry in the funnel plot, the authors
intended to explore the possibility of small study effects and het-
erogeneity as a cause, as well as outcome reporting bias.
Outcome reporting bias can occur when studies measure out-
comes, but do not publish all of them, giving rise to misleading
results (Kirkham 2010). The authors compared the ’Methods’ sec-
tion of each paper to the ’Results’ section to ensure all outcomes
were reported. If they had suspected outcome reporting bias, they
would have contacted the study authors for the data.
Data synthesis
The authors analysed the data using a fixed-effect model, since
there was no evidence of substantial heterogeneity between the in-
cluded studies. If they identify substantial heterogeneity in future
updates of the review, they plan to use a random-effects model.
Subgroup analysis and investigation of heterogeneity
We were not able to combine data from multiple studies in an
analysis, therefore an assessment of heterogeneity was not possible.
In case of moderate to substantial levels of heterogeneity between
the included studies, the authors planned to perform the following
subgroup analyses:
1. age (paediatric, adolescent and adults as defined by the
study investigators);
2. severity of the disease based on lung function (FEV %
predicted: above 90%; 70% to 89%; 40% to 69%; under 40%);
3. participants with acute exacerbations in comparison with
stable CF.
However, since we were unable to combine data from multiple
studies, we have not undertaken any subgroup analysis.
Sensitivity analysis
If the authors hadbeen able to combine studies andhad established
that some of these studies were judged to have a high risk of bias,
in order to test the robustness of their findings they planned to
undertake a sensitivity analysis excluding these studies as long as
at least two studies would still be combined after any exclusions.
However, since we were unable to combine data from multiple
studies, we have not undertaken any sensitivity analysis.
Summary of findings table
As a post hoc change, the current author team present summary of
findings tables for each comparisonof the review.The primary out-
comes of the review and the first five secondary outcomes (partic-
ipant preference, exercise tolerance, adverse effects (e.g. haemopt-
ysis, bronchospasm, desaturation), number of admissions to hos-
pital, need for extra treatment) are presented in the tables and the
quality of the evidence for each outcome of each comparison is
assessed using GRADE methodology (Schünemann 2011).
R E S U L T S
Description of studies
Results of the search
A total of 35 references to 21 individual studies were retrieved
through electronic searches. Seven of these studies were considered
as eligible for inclusion following screening (App 1998;McIlwaine
1991; McIlwaine 2010; Miller 1995; Osman 2010; Pfleger 1992;
Pryor 2010). Of note, the authors have included one study (App
1998) using a German modification of the AD technique (David
1991). Whilst the intervention may not have been strictly to
the guidance of Jean Chevaillier’s description using three dis-
tinct breathing phases, it was felt the technique used was simi-
lar and this study should be included in the evidence. A total of
12 studies were excluded (Giles 1995; Herrero 2016; Lindemann
1992; NCT01885650; NCT02303808; Reix 2012; Roos 1987;
Skopnik 1986; van Ginderdeuren 2001; van Ginderdeuren 2008;
van Ginderdeuren 2011; Warwick 1990). Two studies are await-
ing classification (Davies 2012; Vendrusculo 2017).
The process of the search and study selection is documented in
the PRISMA diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Study characteristics
One randomised studywas of parallel design (Pryor 2010). The re-
maining six studies were of cross-over design; in five of these a two-
arm design was used (App 1998; McIlwaine 2010; Miller 1995;
Osman 2010; Pfleger 1992) and in one study a three-arm design
was used (McIlwaine 1991). A washout period was described in
three of these studies, varying in length between one week (App
1998; Miller 1995) and one month (McIlwaine 1991). A total of
208 participants were randomised with participant numbers vary-
ing between studies; 17 participants in the smallest study (App
1998) and 75 participants in the largest study (Pryor 2010). The
total study duration varied between four days (Miller 1995) and
two years (McIlwaine 2010). The majority of studies, six in to-
tal, were single-centre studies; three were based in the UK (Miller
1995; Osman 2010; Pryor 2010), two in Canada (McIlwaine
1991; McIlwaine 2010) and one in Austria (Pfleger 1992). The
remaining study was a multicentre study based in Germany (App
1998).
Participants
One study was conducted in children (McIlwaine 2010), two in
adults (Osman 2010; Pryor 2010) and four in both adults and
children (App 1998;McIlwaine 1991;Miller 1995; Pfleger 1992).
The age of participants ranged between seven years and 63 years.
The gender of participants was reported in six of the studies with
a ratio of 108 males to 79 females (App 1998; McIlwaine 2010;
Miller 1995; Osman 2010; Pfleger 1992; Pryor 2010). The inclu-
sion criteria in one studywas a hospital admission with an infective
pulmonary exacerbation (Osman 2010), whereas in the remain-
ing six studies participants were clinically stable. One study did
not report any measure of disease severity of the included partici-
pants (App 1998). Lung function at baseline was described in three
studies: one study reported a wide range in FVC (38% to 117%)
(McIlwaine 1991); one measured FEV in litres with a range of
1.9 L to 2.6 L (Pryor 2010); and one study reported amean FEV
of 38% (Osman 2010). Four studies reported Shwachman scores
as a measure of disease severity and each study reported partici-
pants with a wide range of scores (McIlwaine 1991; McIlwaine
2010; Miller 1995; Pfleger 1992).
Interventions
Each of the seven studies varied in their treatment comparisons.
Three studies compared AD to PEP (McIlwaine 1991; Pfleger
1992; Pryor 2010), three studies compared AD to PD&P or just
PD (McIlwaine 1991; McIlwaine 2010; Miller 1995), two studies
compared AD to Flutter® (App 1998; Pryor 2010), one study
comparedADto theCornet® (Pryor 2010), two studies compared
AD to ACBT (Miller 1995; Pryor 2010) and one study compared
participants’ normal airway clearance technique (which included
AD) to HFCWO (Pryor 2010).
In three studies, the duration of each treatment arm was less than
seven days (Miller 1995; Osman 2010; Pfleger 1992). In the re-
maining studies, the duration of each treatment arm ranged from
four weeks to one year (App 1998; McIlwaine 1991; McIlwaine
2010; Pryor 2010).
Outcomes measured
Lung function, specifically FEV , was the most common out-
come measure used and was included in each of the seven stud-
ies. Six of the seven studies also measured FVC and three of
the studies used FEF25−75% as an outcome (McIlwaine 1991;
McIlwaine 2010; Miller 1995). Six studies reported sputum
weight or volume (App 1998; McIlwaine 1991; McIlwaine 2010;
Miller 1995; Osman 2010; Pfleger 1992). Less commonly used
outcomes were oxygen saturation (Miller 1995; Osman 2010),
participant preference (McIlwaine 1991; McIlwaine 2010; Miller
1995; Osman 2010), QoL measures (McIlwaine 1991; Osman
2010; Pryor 2010), hospital admissions or intravenous antibiotic
therapy (McIlwaine 2010; Pryor 2010). LCI has not been mea-
sured in any of the studies to date.
Excluded studies
A total of 10 studies were excluded (Giles 1995; Herrero 2016;
Lindemann 1992; Reix 2012; Roos 1987; Skopnik 1986; van
Ginderdeuren 2001; van Ginderdeuren 2008; van Ginderdeuren
2011;Warwick 1990). The authors felt it was difficult to assess the
relevance of a single treatment session using AD and consequently
excluded three studies using this criteria (Giles 1995; Herrero
2016; Lindemann 1992). One study had not been completed
when the abstractwas published andno further associated abstracts
or papers were found despite correspondence with the study team
(Roos 1987). In three studies the authors considered the interven-
tion not appropriate for this review (Reix 2012; van Ginderdeuren
2001; Warwick 1990). Two studies evaluated inhalation rather
than AD (van Ginderdeuren 2008; van Ginderdeuren 2011) and
in the final study there was no evidence of randomisation (Skopnik
1986).
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Studies awaiting classification
Two studies are listed as ’awaiting classification’ (Davies 2012;
Vendrusculo 2017). One is an RCT of parallel design (Davies
2012). It is a single-centre study based in theUKcomparing partic-
ipants’ usual airway clearance technique (including AD) to airway
clearance using an oscillating device in hospitalised participants
(aged 16 years and over) admitted with a pulmonary infection and
FEV of 15% predicted or over. The primary outcome measure
is the mean % change in FEV ; ad secondary outcome measures
include wet weight of sputum expectorated in 24 hours, length
of time to next course of intravenous antibiotics and the rate of
change of C-reactive protein. The second is an RCT of cross-over
design (Vendrusculo 2017). It compares cardiopulmonary exercise
testing with and without the use of an airway clearance technique
(including AD) prior to the test. It is not clear in either of these
studies how many participants were using AD and whether we
will be able to obtain the specific data for these participants.
Risk of bias in included studies
We used the approach for assessing the risk of bias in included
studies recommended by Cochrane (Higgins 2011) and described
above (Assessment of risk of bias in included studies).
The ‘Risk of bias graph’ illustrates the proportion of studies with
each of the judgements for each entry in the tool (Figure 2), whilst
the ‘Risk of bias summary’ presents the review authors’ judgements
in a cross-tabulation of study by entry (Figure 3). Further details
can be found in the risk of bias sections of the tables describing
the Characteristics of included studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
In four of the seven included studies, the authors failed to spec-
ify how the randomisation sequence was generated. These papers
stated that participants had been randomly assigned to different
treatment groups, but did not clearly define the means of doing
so; hence the risk of bias for sequence generation was unclear in
these studies (App 1998; McIlwaine 1991; Miller 1995; Pfleger
1992). Three studies employed computer randomisation to deter-
mine treatment allocation (McIlwaine 2010; Osman 2010; Pryor
2010), thus their risk of bias due to the sequence generation was
deemed to be low.
Allocation concealment
None of the included studies discussed allocation concealment and
we judged all to have an unclear risk of bias (App 1998;McIlwaine
1991; McIlwaine 2010; Miller 1995; Osman 2010; Pfleger 1992;
Pryor 2010).
Blinding
The airway clearance techniques being compared require the in-
dividual’s participation and, on occasion, the use of manual tech-
niques or mechanical devices. It is not possible to blind by design
and, in this respect, all of the included studies were deemed to
carry a similarly low risk of bias. Conversely, the extent to which
the lack of blinding may have had an effect is unclear, particularly
on the reporting of subjective outcomes such as individual pref-
erence (McIlwaine 1991; Miller 1995) or QoL (McIlwaine 1991;
Osman 2010; Pryor 2010). It is feasible, however, to blind the
individuals collecting data or assessing outcomes to the allocated
treatment group.
Five studies identified that some or all of the outcome assessors had
been blinded and were, therefore, considered to carry a low risk
of bias in this respect (McIlwaine 1991; McIlwaine 2010; Osman
2010; Pfleger 1992; Pryor 2010). In two studies the clinical assess-
ment was carried out by a CF physician blind to the physiotherapy
technique being performed (McIlwaine 1991; McIlwaine 2010).
In another, both the physician and the pulmonary function tech-
nician had been blinded (McIlwaine 2010). Two papers stated that
a blinded, independent investigator or observer had assessed one
or more of the outcome measures (Osman 2010; Pfleger 1992).
Only one paper, however, noted that both the data collection and
the statistical analysis had been performed by blinded observers
(Pryor 2010). Two studies did not discuss the issue of blinding of
outcome assessors and, thus, their risk of bias was deemed unclear
(App 1998; Miller 1995).
Incomplete outcome data
Participant dropout was the primary reason for incomplete out-
come data. Only a single study lasting four days had no with-
drawals and all participants were analysed in the groups to which
they were assigned (Miller 1995). Reasons for withdrawals were
described for the remaining studies and, with the exception of one
paper (McIlwaine 2010), were judged to have a low risk of bias in
this respect.
In addition to the Miller study, only one other paper explicitly
carried out an intention-to-treat analysis for the primary outcome
of FEV (Pryor 2010). However, 13 participants in the Pryor
study did not like the intervention to which they had been allo-
cated and withdrew from the study; it is unclear whether these
participants were included in the intention-to-treat group. The
use of an intention-to-treat analysis was unclear for the remainder
of the included studies (App 1998; McIlwaine 1991; McIlwaine
2010; Osman 2010; Pfleger 1992).
All six studies reporting withdrawals gave reasons for these (App
1998; McIlwaine 1991; McIlwaine 2010; Osman 2010; Pfleger
1992; Pryor 2010). Withdrawal rates ranged from 3.3% of par-
ticipants (Osman 2010) to an overall attrition of 44.4% in the
case of the longest study (McIlwaine 2010). It should be pointed
out that in the McIlwaine study withdrawals at the end of the
first year comprised 13.9% of the participants, but attrition in-
creased to 33.3% of those remaining for the second year of the
study (McIlwaine 2010). The reason for this increase following
the crossing over to the alternate treatment was related to a large
number of participants not returning for the PD&P arm of the
study due to a preference to continue with AD. This, together
with the strong cross-over effect of a further seven participants
who continued with the study whilst incorporating AD into PD&
P, biased the second arm of the study.
Selective reporting
As the study protocols were unavailable, selective reporting was
assessed by comparing the outcomes listed in the ’Methods’ section
with those of the ’Results’ section from each study.
Two studies were considered as having a high risk of selective
reporting (McIlwaine 2010; Pryor 2010). In one study, relevant
baseline characteristics such as FVC and Huang scores were omit-
ted and adherence, which had been closely monitored through-
out, was not reported (McIlwaine 2010). Similarly, the duration
of hospital admissions was recorded but not reported. The Huang
scoring system is applied pre- and post-treatment to evaluate the
therapeutic response to the intervention being studied, taking into
account 20 separate items; 10 clinical, five radiographic and five
pulmonary function parameters. The lower the score, the more
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severe the disease (Huang 1981). In the second study, lung func-
tion and BMI data were not reported at the six-month time frame
as had been stated in the ’Methods’ for the study (Pryor 2010).
We judged one study to have an unclear risk of selective reporting
(App 1998). In this study blood oxygen saturation levels were
recorded during the study but were not commented on in the
paper. As there is no published data available to reflect whether
this parameter changed over the course of the study or as a result of
any intervention received, the risk of selective reporting is deemed
to be unclear (App 1998).
In the four remaining studies, all outcomes described in the ’Meth-
ods’ section were reported in the ’Results’ section, thus there is a
low risk of bias from selective reporting associated with these stud-
ies (McIlwaine 1991; Miller 1995; Osman 2010; Pfleger 1992).
Other potential sources of bias
In one cross-over study, those carrying out AD were asked to per-
form AD breathing exercises during the inhalation of their pre-
treatment nebuliser (Miller 1995). However, those performing
ACBT were asked to breathe normally during the nebulisation
period, potentially introducing bias in the form of an “extra” eight
minutes of treatment time for the AD group. No statistically sig-
nificant differences were found between the two treatment groups
for any of the outcomes measured. Despite this, the risk of bias
was deemed to be high as the stated treatment time for the two
groups was unequal, favouring the AD group.
Out of six cross-over studies, only three of them reported washout
periods between treatment arms; these varied between one week
(App 1998; Miller 1995) and one month (McIlwaine 1991). The
ideal length ofwashout periods is unknown, but the risk of bias due
to carryover effects is certainly higher in short-term studies lacking
any washout period (Pfleger 1992; Osman 2010) and of less sig-
nificance in long-term studies lasting two years (McIlwaine 2010).
However, in the case of those participating in a four-day cross-over
study during an acute respiratory exacerbation, a washout period
is likely to be impractical due to rapid clinical improvements dur-
ing a hospital admission (Osman 2010).
One study was supported by Hill-Rom (manufacturer of the os-
cillating VEST®) and a grant from the Robert Luff Foundation
(Osman 2010). This may be considered as a source of bias. Al-
though Hill-Rom provided devices and equipment for the study,
they did not participate in the design, collection, analysis, inter-
pretation of data or in the writing of the manuscript. Thus, the
risk of bias was deemed to be unclear.
Effects of interventions
See: Summary of findings for the main comparison Autogenic
drainage versus conventional physiotherapy; Summary of
findings 2 Autogenic drainage versus spontaneous cough;
Summary of findings 3 Autogenic drainage versus active cycle of
breathing technique; Summary of findings 4 Autogenic drainage
versus positive expiratory pressure; Summary of findings 5
Autogenic drainage versus Cornet®; Summary of findings 6
Autogenic drainage versus Flutter®; Summary of findings 7
Autogenic drainage versus high frequency chest wall oscillation
Autogenic drainage versus conventional
physiotherapy
Two studies (54 participants) reported on this comparison of AD
versus PD&P (McIlwaine 1991; McIlwaine 2010).
Primary outcomes
1. FEV
Both studies measured FEV (McIlwaine 1991; McIlwaine
2010), but only data from the later study were available for our
analysis (McIlwaine 2010). In this study, the rate of decline in
FEV % predicted for each participant was determined over the
one-year study period. At the 12-month time point, our analysis
found no statistically significant difference between AD and PD&
P, MD -1.12 (95% CI -2.64 to 0.40) (very low quality evidence)
(Analysis 1.1). In the earlier McIlwaine study, lung function was
measured as % change from baseline for each of three two-month
treatment periods using AD, PEP and PD&P (results for the AD
versus PEP arm are reported below). There were no statistically
significant changes in FEV /FVC between the AD and PD&P
treatment periods (McIlwaine 1991).
2. QoL
Questionnaires incorporating a Likert scale 0 - 10 were used to
gauge comfort, level of control and degree of interruption in their
daily life (very low quality evidence). Participants subjectively re-
ported AD to be superior to PD&P (McIlwaine 1991). In the
later study, the participants subjectively felt that AD “worked the
best” and the authors reflected that, collectively, AD gave the par-
ticipants more independence and a greater amount of freedom
in performing their physiotherapy treatment when compared to
PD&P (McIlwaine 2010).
Secondary outcomes
1. Participant preference
The later McIlwaine study reported a preference for AD by all
participants in the study, with many participants refusing to go
back to performing PD&P (very lowquality evidence) (McIlwaine
2010).
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2. Exercise tolerance
Neither study reported on this outcome (McIlwaine 1991;
McIlwaine 2010).
3. Adverse effects
Neither study reported on this outcome (McIlwaine 1991;
McIlwaine 2010).
4. Number of admissions
Only the later study reported on this outcome and provided data
to enter into our analysis (McIlwaine 2010). The authors did not
specify the number of separate individuals admitted to hospital
for pulmonary exacerbations, although they did state that the total
number of hospitalisations per group by the 12-month time point
(13 for the AD group, 16 for the PD&P group) (very low quality
evidence). The published paper reported that mean number of
hospital admissions was not significantly lower in the AD group
compared to the PD&P group; however, in contrast, our analysis
shows the mean number of hospital admissions during the first
year of the study was significantly lower in the AD group, MD -
0.24 (95% CI -0.42 to -0.06) (Analysis 1.2). The reason for this
statistical discrepancy remains unclear and as we have been unable
to further clarify this with the authors of the article, these results
should be interpreted with caution.
5. Need for extra treatment
The later McIlwaine study described 16 hospitalisations for pul-
monary exacerbations in the PD&P group compared to 13 in the
ADgroup in the first year of the study (therewere 18participants in
each group), but the authors did not specify the number of separate
individuals from each group who were hospitalised. The investiga-
tors did report that no participants received home intravenous an-
tibiotic treatment (very low quality evidence) (McIlwaine 2010).
6. Pulmonary function measurements
a. LCI
This outcome was not measured in either study (McIlwaine 1991;
McIlwaine 2010).
b. FVC
Both studies measured FVC (McIlwaine 1991; McIlwaine 2010),
but only data from the later study were available for our analysis
(McIlwaine 2010). In this study, the change in FVC % predicted
was determined over the 12-month study period and analysed as
a parallel study with no statistically significant changes being re-
ported between the treatment methods. In contrast to the pub-
lished paper, our analysis shows statistical significance in favour
of AD, MD 1.88 (95% CI 0.68 to 3.08) (Analysis 1.3). The rea-
son for this statistical discrepancy remains unclear and as we have
been unable to clarify with the authors of the article, these results
should be interpreted with caution. In the earlierMcIlwaine study,
FVCwasmeasured as% change from baseline for each two-month
treatment period using AD and PD&P and there were no signif-
icant changes found between the treatment methods (McIlwaine
1991).
c. FEF25−75%
Both studies measured FEF25−75% (McIlwaine 1991; McIlwaine
2010), but only data from the later study were available for our
analysis (McIlwaine 2010). In this study, the change in FEF25−75%
predicted was determined over the 12-month study period and
analysed as a parallel study with no statistically significant changes
being reported between the treatment methods. In contrast to
the published paper, our analysis shows statistical significance in
favour of PD&P, MD -7.54 (95% CI-10.39 to -4.69) (Analysis
1.4). Once again, the reason for this statistical discrepancy remains
unclear and as we have been unable to further clarify this with
the authors of the article, these results should be interpreted with
caution. In the earlier McIlwaine study, FEF25−75% was measured
as % change from baseline for each two-month treatment period
using AD and PD&P and there were no significant changes found
between the treatment methods (McIlwaine 1991).
7. Oxygen saturation
Neither study reported on this outcome (McIlwaine 1991;
McIlwaine 2010).
8. Sputum weight
Only the earlier studymeasured sputumweight (McIlwaine 1991).
The paper reported that the netweight of sputumproducedduring
ADwas significantly greater (P < 0.01) than that produced during
PD&P, but data were not reported in sufficient detail to enter
into our analysis (McIlwaine 1991). It was noted that sputum
production whilst using ADwas relatively consistent over the two-
month study period.
9. Survival
Neither study reported on this outcome (McIlwaine 1991;
McIlwaine 2010).
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Autogenic drainage versus spontaneous cough
One study (14 participants) used cough alone in a comparison
with AD (Pfleger 1992).
Primary outcomes
1. FEV
There were no significant differences in FEV % predicted be-
tween AD and cough alone when measured at 30 minutes post
physiotherapy, MD 3.00% (95% CI -11.08 to 17.08) (very low
quality evidence) (Analysis 2.1) (Pfleger 1992).
2. QoL
The study did not report on this outcome (Pfleger 1992).
Secondary outcomes
1. Participant preference
The study did not report on this outcome (Pfleger 1992).
2. Exercise tolerance
The study did not report on this outcome (Pfleger 1992).
3. Adverse effects
No adverse effects were reported in this study (very low quality
evidence) (Pfleger 1992).
4. Number of admissions
The study did not report on this outcome (Pfleger 1992)
5. Need for extra treatment
The study did not report on this outcome (Pfleger 1992)
6. Pulmonary function measurements
a. LCI
This outcome was not measured in this study (Pfleger 1992).
b. FVC
There were no significant differences in FVC%predicted between
the treatment groups when measured at 30 minutes post phys-
iotherapy, MD 4.00% (95% CI -10.83 to 18.83) (Analysis 2.2)
(Pfleger 1992).
c. FEF25−75%
Pfleger did not report on this outcome (Pfleger 1992).
7. Oxygen saturation
The study did not report on this outcome (Pfleger 1992).
8. Sputum weight
Pfleger compared cough alone with AD and Hi-PEP alone and in
combination (Hi-PEP results not reported here). It was reported
that all four forms of physiotherapy used in this study produced
significantly more sputum than spontaneous coughing alone (P <
0.001) and our statistical analysis corroborates this, MD 18.33 g
(95% CI 3.11 to 33.55) (Analysis 2.3). However, sputum produc-
tion with AD alone was the lowest and differed significantly from
that of the other physiotherapy treatment groups (Pfleger 1992).
.
9. Survival
The study did not report on this outcome (Pfleger 1992).
Autogenic drainage versus active cycle of breathing
technique
Two studies (48 participants) reported on this comparison (Miller
1995; Pryor 2010). Although 75 participants were included over-
all in the Pryor study, only 15 were randomised to each of the five
treatment groups; therefore the study only contributes 30 partic-
ipants to this pair-wise comparison (Pryor 2010).
Primary outcomes
1. FEV
Both studies reported on FEV , but data were only available
from one study for FEV (L) for our analysis (Pryor 2010). Pryor
reported data at three time points over the 12-month period of
the study - at the start, at six months and at 12 months (Pryor
2010). At the 12-month time point, our analysis found no statis-
tically significant difference between the AD and ACBT groups,
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MD 0.70 L (95% CI -0.09 to 1.49) (very low quality evidence)
(Analysis 3.1). Pryor also reported FEV % predicted and overall
observed a significant deterioration in FEV % predicted over
the 12-month period for the entire cohort (-1.8% predicted; P
= 0.02), stating this decline was within the international average
at the time of the study (Pryor 2010). However, recruitment was
challenging for this long-term study, meaning it was underpow-
ered to detect such a change. Consequently, the results obtained
may have over or underestimated any decline in lung function
identified by the original authors.
Miller (18 participants) measured lung function prior to and fol-
lowing each physiotherapy treatment over the four-day period of
the study, but FEV was not reported specifically (Miller 1995).
The paper stated that taken overall, pulmonary function tests
showed no significant difference between the two methods.
2. QoL
Health-related QoL was measured in one study using the Short
Form-36 (Medical Outcomes Trust, Boston, USA), analysing the
physical and mental domains of the participants (low quality evi-
dence) (Pryor 2010). There were no significant differences in the
physical domain between the groups, though the paper observed
that overall there was a trend towards deterioration over time re-
ported (P = 0.05). Similarly, in the mental domain there were no
significant differences found amongst the groups but there was a
significant deterioration over time reported (P = 0.002).
Pryor also analysed data for the four domains of dyspnoea, fatigue,
emotion and mastery in the Chronic Respiratory Questionnaire
(CRQ) (Guyatt 1987); but found no significant differences in any
domain, although there was a significant improvement in dysp-
noea (P = 0.01) reported over time in the group as a whole (Pryor
2010).
Secondary outcomes
1. Participant preference
Miller reported that nine participants preferred AD, eight par-
ticipants preferred ACBT, and one participant had no preference
(Miller 1995). They went on to qualify that those who preferred
AD to ACBT tended to be those who displayed a greater con-
centration and compliance with treatment. During the course of
the Pryor study, 13 participants withdrew as they did not like the
regimen to which they had been randomised and either reverted
to their original preferred option or chose a different regimen; the
intervention each participant was using was not identified (Pryor
2010). The quality of the evidence from both these studies was
very low.
2. Exercise tolerance
The modified shuttle test was reported in one study (30 partici-
pants), but no data were available for our analysis (Pryor 2010).
No significant difference was found between AD and ACBT (low
quality evidence).
3. Adverse effects
Miller described a decrease in oxygen saturation levels whilst per-
forming ACBT in the moderate to severe group of participants,
but not during any AD sessions (Miller 1995). The authors did
not quantify the extent but did report that in three participants,
one episode was observed and in a fourth participant two episodes
were reported (both morning and afternoon ACBT sessions) (very
low quality evidence).
4. Number of admissions
Neither study reported on this outcome (Miller1995; Pryor 2010).
5. Need for extra treatment
In the Pryor study, some participants in each of the regimens
required intravenous antibiotics during the course of the study;
the median number of courses per group ranged from 1.0 to 1.5
(low quality evidence) (Pryor 2010). The number of participants
and allocated treatment arm was not specified.
6. Pulmonary function measurements
a. LCI
This outcome was not measured in either study (Miller 1995;
Pryor 2010).
b. FVC
Neither study reported this outcome in sufficient detail to enter
into our analysis, but both studies reported there was no statisti-
cally significant difference between the twomethods (Miller 1995;
Pryor 2010). However, Miller reported that more participants
demonstrated an improved FVC with ACBT than AD (Miller
1995).
c. FEF25−75%
This outcome was reported in one study (18 participants), but
not in sufficient detail for inclusion in our analysis (Miller 1995).
The investigators stated that more participants had an improved
FEF25−75% with AD than with the ACBT.
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7. Oxygen saturation
Oxygen saturation levels were reported in one study (18 partici-
pants), but no data were available for our analysis (Miller 1995).
There was no difference found in mean saturation levels of oxygen
between the treatment methods over the four study days. How-
ever, four participants with moderate to severe disease decreased
their oxygen saturation levels during the morning ACBT session,
and one also demonstrating a decrease in the afternoon session.
Participants maintained their oxygen saturation levels during AD
sessions.
8. Sputum weight
Sputum weight was an outcome used in one study (18 par-
ticipants), but no data were available for our analysis (Miller
1995). Sputum was collected and weighed during one hour fol-
lowing physiotherapy treatment. There was no significant differ-
ence found between the AD and ACBT groups.
9. Survival
One participant died during the course of the Pryor study and the
allocated treatment arm was not specified; however, the investiga-
tors stated that the death was unlikely to have been caused by any
intervention under evaluation (Pryor 2010).
Autogenic drainage versus positive expiratory
pressure
A total of three studies (62 participants) reported on this com-
parison (McIlwaine 1991; Pfleger 1992; Pryor 2010). Although
75 participants were included overall in the Pryor study, only
15 were randomised to each of the five treatment groups; there-
fore the study only contributes 30 participants to this pair-wise
comparison (Pryor 2010). Two studies compared AD with PEP
(McIlwaine 1991; Pryor 2010) and one study compared AD to
Hi-PEP (Pfleger 1992).
Primary outcomes
1. FEV
All three studies (62 participants) reported on FEV as an out-
come, but used different units of measurement and we were un-
able to combine any data (McIlwaine 1991; Pfleger 1992; Pryor
2010).
Pryor reported FEV (L) at the start and end of the 12-month
study period (Pryor 2010). At the 12-month time point, our anal-
ysis found no statistically significant difference between the AD
and PEP groups, MD 0.62 L (95% CI -0.30 to 1.54) (low quality
evidence) (Analysis 4.1).
Pryor also reported FEV % predicted and, overall, observed a
significant deterioration in FEV %predicted over the 12-month
period for the entire cohort (-1.8% predicted; P = 0.02), stat-
ing this decline was within the international average at the time
of the study (Pryor 2010). However, recruitment was challeng-
ing for this long-term study, meaning it was underpowered to de-
tect such a change. Consequently, the results obtained may have
over or underestimated any decline in lung function identified
by the original authors. Pfleger reported FEV % predicted was
measured repeatedly before, during and after physiotherapy treat-
ments over the five-day study period (Pfleger 1992); our analysis
found no statistically significant difference between AD and Hi-
PEP at 30minutes following physiotherapy,MD2.00% predicted
(95% CI -12.45 to 16.45) (Analysis 4.2). Finally, in the three-arm
study, McIlwaine measured FEV % predicted at the outset and
at the beginning and end of each of the three two-month study
periods; investigators reported no significant difference in FEV /
FVC when each group performed either AD or PEP, but no data
were available for our analysis (McIlwaine 1991).
2. QoL
Pryor (n = 30) evaluated QoL as an outcome using the Short
Form-36 and CRQ (low quality evidence) (Pryor 2010). For the
Short Form-36 there were no significant differences in the physical
domain between the two groups, but overall the paper reported
that there was a significant trend towards deterioration over time;
similarly, in the mental domain there were no significant differ-
ences found, but there was a significant deterioration reported over
time. For the CRQ there were no significant differences found for
dyspnoea, fatigue, emotion or mastery between the two groups.
Overall, there was a significant improvement in dyspnoea (P =
0.01) reported over time in the group as a whole (Pryor 2010).
Secondary outcomes
1. Participant preference
During the course of the Pryor study (n = 30), 13 participants
withdrew as they did not like the regimen to which they had been
randomised and either reverted to their original preferred optionor
chose a different regimen (low quality evidence). The intervention
each was using at the time was not identified (Pryor 2010).
21Autogenic drainage for airway clearance in cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Exercise tolerance
The modified shuttle test was reported in one study (30 partici-
pants), but no data were available for our analysis (Pryor 2010).
No significant difference was reported between AD and PEP.
3. Adverse effects
None of the studies reported on this outcome (McIlwaine 1991;
Pfleger 1992; Pryor 2010).
4. Number of admissions
None of the studies reported on this outcome (McIlwaine 1991;
Pfleger 1992; Pryor 2010).
5. Need for extra treatment
Pryor reported some participants in each of the regimens required
intravenous antibiotics during the course of the study.The number
of participants and allocated treatment arm was not specified (
Pryor 2010). The median number of courses per group ranged
from 1.0 to 1.5, though statistical analysis was not carried out due
to the small numbers and scattered nature of the data (low quality
evidence).
6. Pulmonary function measurements
a. LCI
This outcome was not measured in any study (McIlwaine 1991;
Pfleger 1992; Pryor 2010).
b. FVC
All three studies (62 participants) measured FVC, but data were
only available from one study for FVC % predicted which was
measured 30minutes followingphysiotherapy (Pfleger 1992).Our
analysis found no statistically significant difference between the
AD and Hi-PEP groups, MD 1.00% (95% CI -13.45 to 15.45)
(Analysis 4.3). There were no significant changes in FVC found in
either of the remaining studies when using AD or PEP (McIlwaine
1991; Pryor 2010).
c. FEF25−75%
One study (18 participants) reported FEF25−75%, but not in suffi-
cient detail to include in our analysis; the investigators reported no
statistically significant changes between AD and PEP (McIlwaine
1991).
7. Oxygen saturation
None of the studies reported on this outcome (McIlwaine 1991;
Pfleger 1992; Pryor 2010).
8. Sputum weight
Two studies (32 participants) used sputum weight as an outcome
(McIlwaine 1991; Pfleger 1992). Data were only available from
one study (14 participants) for our analysis (Pfleger 1992). The
review authors estimated this data from a bar chart in the pub-
lished article, demonstrating that AD showed the lowest sputum
production and PEP the highest (Pfleger 1992). Our analysis of
sputum weight following physiotherapy treatment showed a nu-
merical advantage to PEP, but found no statistically significant
differences between the AD and PEP groups, MD -15.00 g (95%
CI -35.46 to 5.46) (Analysis 4.4). This, however, contrasts with
the published paper, which states statistical significance in favour
of PEP (Pfleger 1992). The data extracted were approximate and
measured from the graph of sputum production, so this probably
accounts for the discrepancy with the results in the published pa-
per.
In one of the three published abstracts relating to the McIlwaine
study (presented at the 17th European Cystic Fibrosis Confer-
ence), the authors reported the net weight of sputum obtained was
significantly greater (P < 0.01) with AD compared to PEP, but the
remaining two abstracts do not state this (McIlwaine 1991). The
unpublished paper which we obtained from the authors does not
fully clarify the matter and we will attempt to address these dis-
crepancies in a future update. However, it was noted that sputum
production whilst using ADwas relatively consistent over the two-
month study period.
9. Survival
One participant died during the course of the Pryor study and the
allocated treatment arm was not specified; however, the investiga-
tors stated that the death was unlikely to have been caused by any
intervention under evaluation (Pryor 2010).
Autogenic drainage versus Cornet®
One study (30 participants) reported on this comparison (Pryor
2010). Although 75 participants were included overall in the Pryor
study, only 15 were randomised to each of the five treatment
groups; therefore the study contributes 30 participants (Pryor
2010).
Primary outcomes
1. FEV
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Pryor reported FEV (L) data at the start and end of the 12-
month study period that was available to enter into our analysis
(Pryor 2010). At the 12-month time point our analysis found no
statistically significant difference between the AD and Cornet®
groups, MD0.74 L (95% CI -0.07 to 1.55) (moderate quality evi-
dence) (Analysis 5.1). Pryor also reported FEV %predicted and,
overall, observed a significant deterioration in FEV % predicted
over the 12-month period for the entire cohort (-1.8% predicted;
P = 0.02), stating this decline was within the international average
at the time of the study (Pryor 2010). However, recruitment was
challenging for this long term study, meaning it was underpow-
ered to detect such a change. Consequently, the results obtained
may have over or underestimated any decline in lung function
identified by the original authors.
2. QoL
Pryor used the Short Form-36 questionnaire and the CRQ and
found no significant difference in the domains between the two
groups (low quality evidence) (Pryor 2010). The results of the
CRQ reportedminimal clinically important differences (improve-
ments) in dyspnoea in the AD group, but not the Cornet® group
over the 12-month study period. However, there was an overall
significant improvement in dyspnoea (P = 0.01) reported over time
in the entire cohort.
Secondary outcomes
1. Participant preference
During the course of the Pryor study, 13 out of 75 participants
withdrew as they did not like the regimen to which they had been
randomised and either reverted to their original preferred option
or chose a different regimen (low quality evidence) (Pryor 2010).
The intervention each was using at the time was not identified.
2. Exercise tolerance
Pryor measured exercise tolerance using the Modified Shuttle Test
and no significant difference was found between AD and Cor-
net® groups (Pryor 2010). No detailed data were available for our
analysis.
3. Adverse effects
Pryor did not report this outcome (Pryor 2010).
4. Number of admissions
Pryor did not report this outcome (Pryor 2010).
5. Need for extra treatment
Pryor reported that some participants in each of the regimens
required intravenous antibiotics during the course of the study
(Pryor 2010). The median number of courses per group ranged
from 1.0 to 1.5, though statistical analysis was not carried out due
to the small numbers and scattered nature of the data (low quality
evidence). The number of participants and allocated treatment
arm was not specified.
6. Pulmonary function measurements
a. LCI
Pryor did not report this outcome (Pryor 2010).
b. FVC
Pryor reported no significant difference in FVC (L) between AD
and Cornet®, but no detailed data were available for our analysis
(Pryor 2010).
c. FEF25−75%
This outcome was not reported in this study (Pryor 2010).
7. Oxygen saturation
The study only reported oxygen saturation levels at baseline in the
participant demographics (Pryor 2010).
8. Sputum weight
This outcome was not reported (Pryor 2010).
9. Survival
One participant died during the course of the Pryor study and the
allocated treatment arm was not specified; however, the investiga-
tors stated that the death was unlikely to have been caused by any
intervention under evaluation (Pryor 2010).
Autogenic drainage versus Flutter®
Two studies (47 participants) reported on this comparison (App
1998; Pryor 2010). Although 75 participants were included over-
all in the Pryor study, only 15 were randomised to each of the five
treatment groups; therefore the study only contributes 30 partic-
ipants to this pair-wise comparison (Pryor 2010).
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Primary outcomes
1. FEV
Both studies reported data for FEV (L) which we could enter
into our analysis (App 1998; Pryor 2010). App recorded lung
function before and after four weeks of treatment using each study
intervention (App 1998). Only the first-arm data from this cross-
over study were used as the authors felt there would be a carryover
effect into the second arm of the study. There was no statistical
difference found between AD and Flutter® at one month, MD
0.10 L (95% CI -0.95 to 1.15)(App 1998) or at 12 months MD
0.21L (95%CI -0.64 to 1.06) (low quality evidence) (Pryor 2010)
(Analysis 6.1). Pryor also reportedFEV %predicted and, overall,
observed a significant deterioration in FEV %predicted over the
12-month period for the entire cohort (-1.8%predicted; P = 0.02),
stating this decline was within the international average at the time
of the study (Pryor 2010). However, recruitment was challenging
for this long-term study, meaning it was underpowered to detect
such a change. Consequently, the results obtained may have over
or underestimated any decline in lung function identified by the
original authors.
2. QoL
One study measured QoL using the Short Form-36 questionnaire
and the CRQ (Pryor 2010). Investigators found no significant
difference in the domains between the two groups (low quality
evidence). However, the latter questionnaire reported an overall
significant improvement in dyspnoea (P = 0.01) over time in the
group as a whole.
Secondary outcomes
1. Participant preference
During the course of one study, 13 out of 75 participants with-
drew as they did not like the regimen to which they had been
randomised and either reverted to their original preferred option
or chose a different regimen (low quality evidence) (Pryor 2010).
The intervention each was using at the time was not identified.
2. Exercise tolerance
The modified shuttle test was reported in one study (30 partici-
pants) and no significant difference was found between AD and
Flutter®. No detailed data were available for our analysis (Pryor
2010).
3. Adverse effects
Neither study reported on this outcome (App 1998; Pryor 2010).
4. Number of admissions
Neither study reported on this outcome (App 1998; Pryor 2010).
5. Need for extra treatment
One study reported some participants in each of the regimens re-
quired intravenous antibiotics during the course of the study (low
quality evidence) (Pryor 2010). The median number of courses
per group ranged from 1.0 to 1.5, though statistical analysis was
not carried out due to the small numbers and scattered nature of
the data. The number of participants and allocated treatment arm
was not specified. The second study reported that two participants
required Intravenous antibiotic treatment (one from from each
group) for an acute exacerbation and were withdrawn from the
study. We are unable to present these data in the graphs as the
paper did not clarify which treatment group the participants were
in when they required the antibiotics (App 1998).
6. Pulmonary function measurements
a. LCI
This outcome was not measured in either study.
b. FVC
Both studies measured FVC (App 1998; Pryor 2010), but only
one study (17 participants) provided data for our analysis (App
1998). There was no statistical difference found between AD and
Flutter® at one month, MD -0.30 L (95% CI -1.50 to 0.90)
(Analysis 6.2). Pryor reported no significant difference in FVC
between AD and Flutter® (Pryor 2010).
c. FEF25−75%
Neither study reported on this outcome (App 1998; Pryor 2010).
7. Oxygen saturation
In both studies oxygen saturation levels were only reported at
baseline as part of the participant demographics (App 1998; Pryor
2010).
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8. Sputum weight
Only one study (17 participants) reported on this outcome with
data we could use in our analysis (App 1998). There was no statis-
tical difference found in sputumweight between AD and Flutter®
at one month, MD -0.90 g (95% CI -3.52 to 1.72) (Analysis 6.3).
9. Survival
One participant died during the course of one study and the allo-
cated treatment arm was not specified; however, the investigators
stated that the death was unlikely to have been caused by any in-
tervention under evaluation (Pryor 2010).
Autogenic drainage versus high frequency chest wall
oscillation
One study reported on this comparison (Osman 2010). However,
as a consequence of the investigators grouping several interven-
tions (AD, Flutter®, PEP and PD&P) as “usual airway clearance
techniques” when comparing them to HFCWO we have limited
data. After contacting Leyla Osman, additional raw data was ob-
tained which identified eight participants using AD alone as their
’normal’ airway clearance technique as a comparison toHFCWO.
This study was performed over four consecutive days alternating
two treatment techniques. Due to the study design it was felt in-
appropriate to present this data in the analysis given the carry-over
effect.
Primary outcome
1. FEV
There was no significant change found in FEV %predicted after
either HFCWO or usual airway clearance techniques compared
to baseline (Osman 2010).
2. QoL
Perceived efficacy and comfort of each airway clearance techniques
and the incidence of urinary leakage during treatment were mea-
sured using 10 cm visual analogue scales (VAS). There was no
significant difference in self-reported comfort and urinary leakage
after either HFCWO or usual airway clearance techniques. Par-
ticipants scored perceived efficacy of their usual airway clearance
techniques significantly higher than for HFCWO (Osman 2010).
Secondary outcomes
1. Participant preference
Of the 29 participants who completed the study, 17 (55%) ex-
pressed a preference for their usual airway clearance technique over
HFCWO (Osman 2010).
2. Exercise tolerance
This outcome was not reported in this study (Osman 2010).
3. Adverse effects
One participant waswithdrawndue to a hypoglycaemic episode. It
is not clear in which treatment arm of the study this event occurred
(Osman 2010).
4. Number of admissions
Inclusion criteria for participants in the Osman study included
hospitalisation with an infective pulmonary exacerbation (Osman
2010).
5. Need for extra treatment
All 29participantswere already receiving intravenous antibiotics as
part of their medical management as inpatients during the course
of this study (Osman 2010).
6. Pulmonary function measurements
Osmandid not report on LCI, FVCor FEF25−75% (Osman 2010).
7. Oxygen saturation
There was no significant change found in oxygen saturation levels
after either HFCWO or usual airway clearance techniques com-
pared to baseline, but no information was provided for the com-
parison between groups (Osman 2010).
8. Sputum weight
Significantly more sputum was expectorated with usual airway
clearance techniques than with HFCWO during both a single
treatment session and over a 24-hour period, MD 4.4 g and 6.9 g
respectively (P < 0.001) (Osman 2010).
9. Survival
This outcome was not reported in this study (Osman 2010).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
AD compared with spontaneous cough for CF
Patient or population: adults and children with CF
Settings: outpat ients
Intervention: AD
Comparison: spontaneous cough
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Spontaneous cough AD
FEV % predicted
Follow-up: each treat-
ment performed on 1
day
See comment. NA 14 participants
(1 study)
⊕©©©
very low1,2,3
There was no signif i-
cant dif f erence between
groups in terms of FEV
(% predicted)
QoL Not reported. NA NA NA
Participant preference Not reported. NA NA NA
Exercise tolerance Not reported. NA NA NA
Adverse events
Follow-up: each treat-
ment performed on 1
day
See comment. NA 14 participants
(1 study)
⊕©©©
very low1,2,3
No adverse events were
reported during the
study.
Number of admissions
to hospital
Not reported. NA NA NA
Need for extra treat-
ment
Not reported. NA NA NA
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* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in 1 second; NA: not applicable; QoL: quality of lif e.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison. As results were not
presented f rom paired analyses for one study, we treated the cross-over studies as if they were parallel studies which is a
conservat ive approach as it does not take into account within-pat ient correlat ion.
2. Downgraded once due to risk of bias; inconsistency between methods described and results reported regarding t ime for
individuals to clear lungs.
3. Downgraded once due to applicability; each treatment performed only once and very lim ited follow up (less than 1 week).
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AD compared with ACBT for CF
Patient or population: adults and children with CF
Settings: outpat ients
Intervention: AD
Comparison: ACBT
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ACBT AD
FEV (L)
Follow-up: up to 12
months
The mean FEV was 1.
94 L in the ACBT group
(also see comment)
The mean FEV was
0.70 L higher (0.09
L lower to 1.49 L
higher) in the autogenic
drainage group (also
see comment)
NA 44 participants
(2 studies)
⊕⊕©©
low1,2
Data were available for
analysis for 26 part ic-
ipants f rom 1 study.
A signif icant deteriora-
t ion in FEV (% pre-
dicted) was also ob-
served for the cohort of
this study
No signif icant dif f er-
ences in pulmonary
funct ion tests in the
other study
QoL (SF-36 and CRQ)
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
There were no signif -
icant dif f erences be-
tween groups in the
mental and physical do-
mains of the SF-36.
There were no signif -
icant dif f erences be-
tween the dyspnoea,
fat igue, emotion and
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mastery domains of the
CRQ
Participant preference
Follow-up: up to 12
months
See comment. NA 44 participants
(2 studies)
⊕©©©
very low1,2,3
1 study reported that
9 part icipants preferred
AD, 8 part icipants pre-
ferred ACBT and 1 par-
t icipant had no prefer-
ence
In the other study 13
out of the total of 75
part icipants (all t reat-
ments in the study)
withdrew as they did
not like the treatment
they were randomised
to (not specif ied by in-
tervent ion)
Exercise tolerance
(modified shuttle test)
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
No signif icant dif f er-
ence between groups.
Adverse events
Follow-up: 2 days
See comment. NA 18 participants
(1 study)
⊕©©©
very low1,2,4
1 study reported a de-
crease in oxygen satu-
rat ion levels in 4 par-
t icipants in the ACBT
group but no part ici-
pants experienced this
during any AD sessions
Number of admissions
to hospital
Not reported. NA NA NA
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Need for extra treat-
ment
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
The median number of
ant ibiot ics courses per
treatment group ranged
f rom 1.0 to 1.5 (no fur-
ther information given)
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; ACBT : act ive cycle of breathing technique; CRQ: Chronic Respiratory Quest ionnaire; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory
volume in 1 second; NA: not applicable; QoL: quality of lif e; SF-36 : short form 36.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison.
2. Downgraded once due to unclear risk of bias; many elements of study designs not clearly described.
3. Downgraded once due to risk of bias; by design, study cannot be blinded and lack of masking may have inf luenced
subject ive outcomes. Further no details of treatment used prior to baseline reported, which may also have inf luenced
subject ive outcomes.
4. Downgraded once due to applicability; each treatment performed only once and very lim ited follow up (less than one week).
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AD compared with PEP for CF
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: AD
Comparison: PEP
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PEP AD
FEV (L)
Follow-up: up to 12
months
The mean FEV was 2.
02 L in the PEP group
(also see comment)
The mean FEV was
0.62 L higher (0.30 L
lower to 1.54 L higher)
in the AD group (also
see comment)
NA 62 participants
(3 studies)
⊕⊕©©
low1,2
Data were available for
analysis for 26 part ic-
ipants f rom 1 study.
A signif icant deteriora-
t ion in FEV (% pre-
dicted) was also ob-
served for the cohort of
this study
In the other 2 studies,
there was there was
no signif icant dif f er-
ence between groups in
terms of FEV
QoL (SF-36 and CRQ)
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
There were no signif -
icant dif f erences be-
tween groups in the
mental and physical do-
mains of the SF-36.
There were no signif -
icant dif f erences be-
tween the dyspnoea,
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f at igue, emotion and
mastery domains of the
CRQ
Participant preference
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
13 out of the total
of 75 part icipants (all
t reatments in the study)
withdrew as they did
not like the treatment
they were randomised
to (not specif ied by in-
tervent ion)
Exercise tolerance:
modified shuttle test
Follow-up: up to 12
months
See comment. NA NA NA No signif icant dif f er-
ence between groups.
Adverse events Not reported. NA NA NA
Number of admissions
to hospital
Not reported. NA NA NA
Need for extra treat-
ment
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
The median number of
ant ibiot ics courses per
treatment group ranged
f rom 1.0 to 1.5 (no fur-
ther information given)
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CRQ: Chronic Respiratory Quest ionnaire; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in 1 second; NA: not applicable;
PEP: posit ive expiratory pressure; QoL: quality of lif e; SF-36 : short form 36.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison. As results were not
presented f rom paired analyses for one study, we treated the cross-over studies as if they were parallel studies which is a
conservat ive approach as it does not take into account within-pat ient correlat ion.
2. Downgraded once due to risk of bias; inconsistency between methods described and results reported regarding t ime for
individuals to clear lungs and many elements of study designs not clearly described.
3. Downgraded once due to risk of bias; by design, study cannot be blinded and lack of masking may have inf luenced
subject ive outcomes. Further no details of treatment used prior to baseline reported, which may also have inf luenced
subject ive outcomes.
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AD compared with Cornet® for CF
Patient or population: adults with cyst ic f ibrosis
Settings: outpat ients
Intervention: AD
Comparison: Cornet®
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Cornet® AD
FEV (L)
Follow-up: up to 12
months
The mean FEV was 1.9
L in the Cornet® group
(also see comment)
The mean FEV was
0.74 L higher (0.07 L
lower to 1.55 L higher)
in the AD group (also
see comment)
NA 27 participants
(1 study)
⊕⊕⊕©
moderate1
Data for 27 part icipants
were available for anal-
ysis. A signif icant de-
teriorat ion in FEV (%
predicted) was also ob-
served for the cohort of
this study
QoL (SF-36 and CRQ)
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,2
There were no signif -
icant dif f erences be-
tween groups in the
mental and physical do-
mains of the SF-36.
There were no signif -
icant dif f erences be-
tween the dyspnoea,
fat igue, emotion and
mastery domains of the
CRQ
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Participant preference
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,2
13 out of the total
of 75 part icipants (all
t reatments in the study)
withdrew as they did
not like the treatment
they were randomised
to (not specif ied by in-
tervent ion)
Exercise tolerance:
modified shuttle test
Follow-up: up to 12
months
See comment. NA NA NA No signif icant dif f er-
ence between groups.
Adverse events Not reported. NA NA NA
Number of admissions
to hospital
Not reported. NA NA NA
Need for extra treat-
ment
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,2
The median number of
ant ibiot ics courses per
treatment group ranged
f rom 1.0 to 1.5 (no fur-
ther information given)
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CRQ: Chronic Respiratory Quest ionnaire; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in 1 second; NA: not applicable;
QoL: quality of lif e; SF-36 : short form 36.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison.3
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2. Downgraded once due to risk of bias; by design, study cannot be blinded and lack of masking may have inf luenced
subject ive outcomes. Further no details of treatment used prior to baseline reported, which may also have inf luenced
subject ive outcomes.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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AD compared with Flutter® for CF
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: AD
Comparison: Flut ter®
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Flutter® AD
FEV (L)
Follow-up:up to 12
months.
The mean FEV was 0.21 L higher (0.64 L
lower to 1.21 L higher) in the AD group in the
parallel study
The mean FEV was 0.10 L higher (0.95 L
lower to 1.15 L higher) in the AD group in the
cross-over study
NA 39 participants
(2 studies including one
cross-over study)4
⊕⊕©©
low1,2
A signif icant deteriora-
t ion in FEV (% pre-
dicted) was also ob-
served for the cohort of
the parallel study
QoL (SF-36 and CRQ)
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
There were no signif -
icant dif f erences be-
tween groups in the
mental and physical do-
mains of the SF-36.
There were no signif -
icant dif f erences be-
tween the dyspnoea, fa-
t igue, emotion and mas-
tery domains of the CRQ
Participant preference
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
13 out of the total of
75 part icipants (all t reat-
ments in the study) with-
drew as they did not
3
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l ike the treatment they
were randomised to (not
specif ied by interven-
t ion)
Exercise tolerance:
modified shuttle test
Follow-up: up to 12
months
See comment. NA NA NA No signif icant dif f er-
ence between groups.
Adverse events Not reported. NA NA NA
Number of admissions
to hospital
Not reported. NA NA NA
Need for extra treat-
ment
Follow-up: up to 12
months
See comment. NA 30 participants
(1 study)
⊕⊕©©
low1,3
The median number of
ant ibiot ics courses per
treatment group ranged
f rom 1.0 to 1.5 (no fur-
ther information given)
* The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CRQ: Chronic Respiratory Quest ionnaire; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in 1 second; NA: not applicable;
QoL: quality of lif e; SF-36 : short form 36.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; small numbers of part icipants included in the comparison.
2. Downgraded once due to unclear risk of bias; many elements of study designs not clearly described.
3. Downgraded once due to risk of bias; by design, study cannot be blinded and lack of masking may have inf luenced
subject ive outcomes. Further no details of treatment used prior to baseline reported, which may also have inf luenced
subject ive outcomes.
4. Data f rom the cross-over study were analysed at the end of the f irst treatment period, before cross-over occurred.38
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AD compared with HFCWO for CF
Patient or population: adults with cyst ic f ibrosis
Settings: hospital admission
Intervention: AD
Comparison: HFCWO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
HFCWO AD
FEV Not reported1. NA NA NA
QoL Not reported1. NA NA NA
Participant preference Not reported1. NA NA NA
Exercise tolerance
(modified shuttle test)
Not reported1. NA NA NA
Adverse events Not reported1. NA NA NA
Number of admissions
to hospital
Not reported1. NA NA NA
Need for extra treat-
ment
Not reported1. NA NA NA
*The basis for the assumed risk (e.g. the median control group risk across studies) is the event rate or mean risk in the control group unless otherwise stated
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AD: autogenic drainage; CF: cyst ic f ibrosis; CI: conf idence interval; FEV : f orced expiratory volume in 1 second; HFCWO: high f requency chest wall oscillat ion; NA: not
applicable; QoL: quality of lif e.
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. No outcome data presented as several intervent ions (AD, Flutter® , posit ive expiratory pressure and convent ional
physiotherapy) were grouped together as as ‘‘usual airway clearance techniques’’ and compared to HFCWO. Insuf f icient
data comparing AD and HFCWO.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
The aim of this review was to determine the effectiveness of AD,
particularly the impact on lung function and QoL in people with
CF compared to other airway clearance techniques or no physio-
therapy. Single-treatment studies were excluded because the short-
term outcomes measured were not of relevance to people with CF.
We identified seven studies eligible for inclusion in this review;
six were published as full papers and one as an abstract only. The
authors of the abstract have kindly provided the full report of that
study (McIlwaine 1991). The included studies compared AD to
one ormore recognised airway clearance techniques includingPEP,
ACBT, conventional physiotherapy (PD&P) and oscillatory de-
vices (Flutter®, Cornet® and HFCWO). These techniques have
been evaluated by other reviews (Main 2005; McIlwaine 2015;
Mckoy 2016; Morrison 2017).
A total of 208 participants were randomised in the seven studies
(numbers ranging from 17 to 75). The length of individual studies
varied from four days to two years. Six studies enrolled clinically
stable people with CF and one enrolled participants experiencing
an exacerbation of their chest condition. Due to the heterogeneity
of the studies, data analysis was not possible for most outcomes.
In terms of primary outcome measures, FEV was reported in all
seven included studies. Changes in FEV were not significantly
different for AD compared to other airway clearance techniques.
The rate of decline in FEV in participants using AD over the
course of a year-long parallel study was comparable to that of a
group using a variety of airway clearance techniques (ACBT, PEP,
Cornet® and Flutter®) (Pryor 2010). However, recruitment was
challenging for this long-term study which meant it was under-
powered to detect such a change and consequently any results may
have under or overestimated any decline in lung function identi-
fied by the original authors.
Three of the seven studies measured the impact of airway clear-
ance on health-related QoL, but only one study used validated
scales (Pryor 2010). Measures of QoL such as dyspnoea in the AD
group were comparable with those observed in the other treatment
groups (Pryor 2010). Similarly, when using a non-validated Likert
scale, there was evidence to suggest that AD, together with PEP
treatment modalities, may be seen as preferable to PD&P in terms
ofQoLmeasures (McIlwaine 1991).One study comparedADand
a variety of other airway clearance techniques to HFCWO and
reported no significant difference in comfort and urinary leakage
(Osman 2010). Participants in this study scored perceived efficacy
of their usual airway clearance techniques, including AD, signifi-
cantly higher than for HFCWO (Osman 2010).
Personal preference was assessed in two studies where participants
were older children or adults (McIlwaine 2010; Miller 1995).
Participants in one study preferred AD over PD&P (McIlwaine
2010), but the second study showed no difference between AD
and ACBT (Miller 1995). Personal preference is associated with
greater adherence to therapy, but is also subject to variability over
the course of a lifetime (Flume 2009). A transient fall in oxygen
saturation levels was reported for ACBT in one study but not for
AD (Miller 1995).
With respect to other secondary outcomes, one study assessed ex-
ercise tolerance (Pryor 2010). Investigators found no significant
differences between the treatment groups (Pryor 2010). Analysis
of the data from a single long-term study of people with CF with
stable disease which compared AD to PD&P demonstrated a re-
duced number of mean (SD) hospital admissions over 12 months
in the 12 to 18 years age group undertaking AD (1.00 (0.32) ver-
sus 0.76 (0.18)) resulting in MD -0.24 (95% CI -0.42 to -0.06).
In contrast, this was reported as non-significant by the study in-
vestigators (McIlwaine 2010). Six of the seven included studies
reported FVC and three of the studies reported FEF25−75%; results
of these outcome measures showed AD was not significantly dif-
ferent to any of the other treatments under investigation in either
short- or long-term studies. One study suggested better sputum
production with AD (McIlwaine 1991), but not consistently com-
pared to other techniques (Pfleger 1992). It is difficult to assess
the impact of sputum production on people with CF, particularly
those with mild disease. These studies describe wet weight of spu-
tum which can be unreliable taking into account underestimating
due to swallowing sputum or overestimating due to inclusion of
saliva.
There is no evidence thatAD is superior to other airway techniques
when considering the primary and secondary outcomes assessed
in the review.
Overall completeness and applicability of
evidence
The literature includes representation from both adults and chil-
dren (range seven to 63 years); five out of seven studies included
participants under the age of 16. Studies recruited participants
with mild to severe disease. Three cross-over studies were consid-
ered short term (less than seven days duration). A further three
cross-over studies and one of parallel design were considered long
term and ranged from eight weeks to two years.
The literature is relevant and representative of the majority of
airway clearance techniques currently available to people with CF;
three studies compared AD to PD&P, two studies used AD versus
ACBT as a comparison, three studies compared AD to PEP and
a total of four studies compared AD to an oscillating device - one
study compared AD to the Cornet®, two studies compared it to
Flutter®, and one study compared AD to HFCWO. There were
no studies comparing AD to acapella, intrapulmonary percussive
ventilation (IPV) or Quake® devices; or to exercise.
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The applicability of the available evidence needs to be considered
in light of the fact that some of the studies were undertaken 18
years ago. General improvements in clinical condition of people
with CF need to be taken into account as there have been well-
documented improvements in respiratory condition.
It should also be noted that the most recent national annual CF
registry reports cite exercise as one of the most frequently used
primary or secondary forms of airway clearance amongst both
adult and paediatric populations (CFF 2015; New Zealand CF
Association 2013; UK CF Trust 2015). Whilst this is not neces-
sarily representative of current international practice outside the
aforementioned countries, it is, nonetheless, a form of treatment
which is likely to be available to the majority of people with CF.
In this review, none of the included studies used exercise as a com-
parator intervention and only one study measured exercise capac-
ity as an outcome measure (Pryor 2010).
Quality of the evidence
We have included seven RCTs, enrolling 208 participants. Six
studies were published as full papers and one in abstract form only.
A copy of the unpublished paper was obtained following corre-
spondence with the authors (McIlwaine 1991). Studies compared
AD to a variety of airway clearance techniques and six studies used
a cross-over design. A recent study examining cross-over studies in
Cochrane Reviews found that the studies’ analysis and presenta-
tion of results were often not appropriate or clear, with less than a
third of studies presenting results that could be included in ameta-
analysis (Nolan 2016) .ValidatedQoLmeasures were not available
for the earlier studies (Gee 2000; Quittner 2009).
Overall, the quality of the evidence from the studies was judged
to be mainly low or very low (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3;
Summary of findings 4; Summary of findings 5; Summary of
findings 6; Summary of findings 7). We judged only one lung
function outcome for one comparison (AD versus Cornet®) to
have moderate quality of evidence (Summary of findings 5). The
main reasons for downgrading the levels of evidence were the small
numbers of participants, the lack of clarity of the reporting in the
studies and the inability to blind participants.
With regard to study design, while the blinding of participants
or research staff is challenging for this intervention, blinded out-
come assessors were used in all but two of the studies (App 1998;
Miller 1995), improving the quality of the evidence gathered and
reducing the risk of detection bias. One study reported the use of
a blinded statistician (Pryor 2010). Three studies describe appro-
priate methods of random sequence generation and carry a low
risk of bias in this respect (McIlwaine 2010; Osman 2010; Pryor
2010); but none of the included studies reported on the allocation
concealment process. Half of the cross-over studies described us-
ing a washout period, raising the potential for carryover effects and
may influence outcomes recorded in the second arm of a study.
Of note regarding reporting issues, one two-year cross-over study
was judged to have a high risk of bias due to incomplete outcome
data (Figure 3). The authors acknowledged that data from the
second arm of the study was affected by high dropout rates (59%)
andnon-adherence (41%) in the PD&Parm (McIlwaine 2010). In
addition, this studywas considered to have selective reporting bias,
as FVC, chest x-ray scores and hospital admissions were measured,
but not reported (McIlwaine 2010).
Furthermore, the tools used to record personal preference in the
included studies were generally not well-described or validated;
and no study incorporated measures of adherence.
Potential biases in the review process
Adequate searches identified relevant studieswith relatively limited
participant numbers. Four studies were conducted more than 18
years ago and additional data requested from the authors were not
available. In one study, AD was included with a number of other
airway clearance techniques and compared to HFCWO, which
limited the data available for this review (Osman 2010).
Two authors (PM, PB) use AD in their clinical practice, but are not
sponsored by any institution and have not been paid to provide
training on this technique.
Agreements and disagreements with other
studies or reviews
Previous Cochrane Reviews of conventional physiotherapy (Main
2005), ACBT (Mckoy 2016), PEP therapy (McIlwaine 2015) and
oscillating devices (Morrison 2017) have not identified one tech-
nique to be significantly superior and this is consistent with the
current review. There is no clear evidence to support the use of
one airway clearance technique over another, but there is a reason-
able base to support some form of airway clearance, particularly
in productive people with CF (Warnock 2015).
A Canadian team have undertaken a systematic review of AD and
arrived at similar conclusions to this review, albeit by a slightly dif-
ferent route (Morgan 2015). Their published paper outlines the
appropriate methodology they have employed and the majority of
studies they selected are the same as in this review. They did not
include one study which is included in this review as they felt the
approach to AD was distinct (App 1998). Whilst the intervention
may not have been strictly to the guidance of Jean Chevaillier’s
description, we felt it important to include this evidence (App
1998). They also included one study which assessed outcomes af-
ter a single treatment (Giles 1995).We decided not to select single
treatment studies, for two reasons. Firstly, we did not feel these
studies examined outcomes that were of relevance to people with
CF and secondly, a single treatment does not enable the individual
to establish confidence and expertise with the technique. A sep-
arate South African team have also examined AD and presented
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their conclusions in a conference abstract (Corten 2015). They
undertook a systematic review evaluating the effect of AD and
assisted AD compared to no physiotherapy, sham physiotherapy,
or other methods of physiotherapy in children with CF (Corten
2015). Assisted AD is a passive technique used with babies and
young children involving manual compression over the chest wall
during expiration. We did not include this technique, as it is quite
distinct from AD. Seven studies were identified in the Corten re-
view, which concluded there was insufficient evidence to deter-
mine the efficacy and safety of AD and assisted AD in children.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Autogenic drainage (AD) is a challenging technique that requires
commitment from the individual. As such, it is important that
this intervention is reviewed to ensure its effectiveness for people
with cystic fibrosis (CF). It is comparable to other airway clearance
techniques and may be considered as an alternative technique in
a targeted patient group, e.g. those well-motivated, who want to
explore techniques that support their independence. However, the
authors of an early study reported that three children aged 11
years performed poorly with AD, finding it difficult to concentrate
for the required period whilst learning the technique (McIlwaine
1991). It is important to consider the age-appropriateness of the
therapy techniques, particularly in younger people with CF who
may find AD challenging. Furthermore, individual preference and
acknowledgement of personal health beliefs are important factors
in optimising adherence to airway clearance regimens suggested
or offered (Flume 2009).
The included studies did not compare AD to exercise alone, al-
though exercise is regularly used as an alternative to more for-
mal airway clearance techniques (CFF 2015; New Zealand CF
Association 2013; UK CF Trust 2015). More information is re-
quired to evaluate the effectiveness of exercise alone for airway
clearance compared to all other techniques.
Implications for research
It is important to consider the changing clinical condition of our
patient cohort, many of whom are now identified through new-
born screening and consequently have improved clinical status.
In light of the many variables which influence the measurement of
forced expiratory volume in one second (FEV ) in the short term,
some studies are focusing on frequency of exacerbation and time to
next exacerbation as primary outcome measures (Konstan 2007;
VanDevanter 2015). Despite these variables, FEV remains the
pulmonary function test parameter with the most validity when
considering relatively short-term study outcomes, as it correlates
well with other outcomes, such as quality of life (QoL) and sur-
vival, which are important to people with CF. Given that the pro-
posed physiological impact of AD is to augment airway clearance,
measures of ventilatory capacity such as lung clearance index (LCI)
are attractive and potentially may provide more sensitive identifi-
cation of early lung disease and response to interventions such as
AD. Currently there is insufficient external validity of this mea-
sure to include it as a primary outcome, but it will represent an
important secondary outcome in future reviews.
Themajority of studies in this review were of cross-over design and
several of these described changing from one technique to another
with no washout period. The magnitude and duration of carry-
over effects are unknown in the CF population, but can influence
the second armof a study (Nolan 2016; Southern2003). Itmust be
noted that, especially in cross-over studies, participant preference
can also impact uponwithdrawals andmay limit the overall quality
of a body of evidence (Pryor 2010). For this reason, future studies
examining AD should avoid a cross-over design where possible, or
should be designed to include an adequate washout period.
Incorporating a validated personal preference tool, measures of
adherence and health-related QoL in future research would pro-
mote a patient-centred approach to clinical practice and would
provide the clinical insight to respond to the needs of the individ-
ual. The acquisition of meaningful data from further long-term,
randomised controlled studies utilising large cohorts to control for
participant variability when comparing airway clearance modali-
ties is required to rigorously evaluate AD and other airway clear-
ance techniques.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
App 1998
Methods RCT.
Cross-over design: AD or Flutter® therapy used for 4 weeks each with an additional one-
week “washout period” prior to starting each arm, without any kind of physiotherapy
administered
Multicentre.
Location: Germany.
Participants 17 participants with CF diagnosed by clinical history and a positive sweat test
17 initially randomised, 3 dropouts reported (1 for time-related reasons and the other 2
for acute bronchopulmonary exacerbation), therefore 14 analysed (7 in each treatment
group)
Age: range 7 to 41 years; mean (SD) 19.6 (10.3) years.
Gender split: 6 male, 8 female.
Interventions Treatment 1: 2x daily AD for 30 minutes.
Treatment 2: 2x daily Flutter® therapy for 30 minutes.
Outcomes Respiratory function (FEV , FVC) measured at the beginning and end of each 4-week
therapy cycle. Measurements were taken before and after 30 minutes physiotherapy
Sputum volume (wet) was collected, weighed and stored at the end of each physiotherapy
session
Blood oxygen saturation levels measured by pulse oximetry technique
This paper also considered the implications of the Flutter® on sputum viscoelasticity
but this was not an outcome measured in this review
Notes Only first-arm data used for analysis as it was felt a 1-week washout was insufficient to
exclude a carry-over effect into the second arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper only states that patients were “ran-
domly assigned to one of the two treatment
arms”. Method of randomisation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not stated. Insufficient information pro-
vided about the concealment of allocation
process
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
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App 1998 (Continued)
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants ’dropped out’ with reasons
stated: 1 for business-related time con-
straints after the first examination; and the
other 2 for acute bronchopulmonary exac-
erbations during the course of the study (1
from each arm)
Selective reporting (reporting bias) Unclear risk Oxygen saturation levels were taken but
only reported at baseline. It is unknown
whether this parameter changed over the
course of the study or as a result of any in-
tervention received
FEV and FVC baseline characteristics
given as % predicted values. However, the
values recorded during the study are not
presented as % predicted but as absolute
figures (L)
Other bias Low risk None identified.
McIlwaine 1991
Methods RCT.
Cross-over design: participants randomised into 3 groups (PD&P, ADandPEP) and used
this technique for the first “treatment period” of 2 months, they sequentially performed
the other techniques. Each treatment technique was separated by an interval of 1 month
“off period” when the pre-study regimen of PD was reinstated
Single centre.
Location: Canada.
Participants 18 participants with CF diagnosed by sweat test > 60 mEq/L.
Age: mean (range) 17.3 (11 to 27) years.
FVC: range 38% predicted to 117% predicted.
Shwachman score: range 50 - 94.
Interventions Technique 1: 2x daily PEP mask treatment in sitting using cycles of 15 tidal volume
breaths against a resistor creating a PEP of between 10 - 20 cms H 0 followed by FET
and cough. Sequence repeated 6 times or for a minimum of 20 minutes (whichever was
longer).
Technique 2: 2x PD&P (PD&P, vibrations, deep breathing and FET) performed in
11 different PD positions, draining 6 positions in the morning and the other 5 in the
afternoon. Treatment time of 30 minutes each session.
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McIlwaine 1991 (Continued)
Technique 3: 2x AD performed in sitting until all mucus was evacuated (maximum
treatment session length no more than 45 minutes)
Outcomes FEV , FVC, and FEF25-75% clinical assessment and Shwachman score were measured
at the start and end of each 2-month treatment period.
Sputum expectorated during the weekly physiotherapist-supervised physiotherapy ses-
sion was collected and weighed
Other measures included reported treatment duration, treatment comfort, requirement
for assistance with treatment, flexibility of treatment times, control in performing own
treatment, and how interruptive treatment was to daily living. Physical activity and
compliance with treatment were monitored using a weekly questionnaire
Notes Unpublished paper obtained from authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated. “In order to avoid seasonal vari-
ations which may have affected the out-
come of the study, the patients were ran-
domized into three groups. Each group was
assigned by a different physiotherapy regi-
ment for the first treatment period, then se-
quentially performed the other techniques”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
overall. The extent to which the lack of
blinding may have had an effect on the re-
porting of subjective outcomes such as pa-
tient preference and QoL measures is un-
clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physician was not told what type of phys-
iotherapy was being performed by the par-
ticipant at the time of assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The results are reported from 14/18 par-
ticipants who completed the study, 4 with-
drawals discussed. 1 participant required
hospitalisation during the first period of the
study (treatment regimen was PD&P) due
to exacerbation of her pulmonary disease
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McIlwaine 1991 (Continued)
and was found to have ABPA. She was then
considered too unstable to continue in the
study. A second participant was dropped
at the end of the first period, after requir-
ing Prednisone to control an allergic reac-
tion to an antibiotic. 2 other participants
(treatment regimen AD) refused to com-
plete the cross-over study, instead they in-
sisted on continuing AD. These partici-
pants were excluded from the analysis of
sputum production
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk None identified.
McIlwaine 2010
Methods RCT.
Cross-over design.
Single paediatric centre.
Location: Canada.
Participants 36 participants with ”proven diagnosis“ of CF.
Age: 12 - 18 years.
Shwachman score 65 - 98.
Compliant performing daily chest physiotherapy using PD&P technique for at least 1
year prior to the study
Interventions Treatment 1: 2 sessions of AD 30 min daily in sitting. The length of time to complete
this technique varied with each participant but on average required 30 minutes
Treatment 2: 2 sessions of PD&P approximately 30 min daily, 6 positions drained in
morning and 5 in evening using percussion, deep breathing exercises combined with
vibrations on expiration. This was followed by huffs
Each treatment regimen was performed for 1 year before crossing over to the other
treatment regimen for a further year
Outcomes FEV , FVC, FEF25−75% sputum weight (partial and subjective), number of hospital
admissions, participant preference, andneed for extra treatment. A change in Shwachman
and Huang scores were also measured
Notes The study was powered as a 2-year cross-over study. Only data from the first year were
reported due to 10/17 participants from Group B (AD-PD&P) withdrawing from the
study before starting PD&P arm; this completely biased the results. “No formal matched
cross-over analysis of the data could be performed.” Also, “...as the studywas not powered
to detect single group differences, these resultsmay not truly reflect treatment differences.
”
Sputum weight was not measured by the investigators, but it was the participants who
”reported an increased expectoration with AD“
52Autogenic drainage for airway clearance in cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McIlwaine 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were matched as pairs, using
FEV (within 15%) as the primary match,
Shwachman scores (within 15 points), age
(within 3 years) and same sex as secondary
matches. Members of each pair were ran-
domly assigned by computer to 1 of the 2
groups (A or B)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of of bias is deemed to be
low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”...full clini-
cal assessment, including Shwachman and
Huang scores, performed at the CF clinic
by physician blinded as to the method of
physiotherapy the patient was performing
in the study...” and “The pulmonary func-
tion technician was blinded as to the pa-
tient’s physiotherapy technique.”
Not stated if statistician was blinded or not.
Incomplete outcome data (attrition bias)
All outcomes
High risk 36 participants entered the study. Data on
33 available at 12months. 3withdrew from
the study in the first year: 2 in Group A
(pregnancy, ABPA), 1 in Group B (non-
compliant). In the first year of the study,
33 stayed in the group to which they were
randomised. In the 2nd year, 10/17 partic-
ipants from Group B (AD/PD) did not re-
turn for PD&P arm of study, due to prefer-
ence to continue with AD (completely bi-
ased 2nd arm of study). Strong cross-over
effect in 7 participants who continued with
the study as they incorporated AD breath-
ing technique into PD&P; therefore only
year 1 data reported. The results from the
2nd year could not be analysed as single-
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McIlwaine 2010 (Continued)
groupdifferences could not be studied. Sec-
ondary analysis of PFTs in Group A (PD&
P, then AD) comparing years 1 and 2 was
performed but no significant differences
were found
Selective reporting (reporting bias) High risk “Full clinical assessment” was undertaken
and would include weight and height,
but these are not reported. Adherence
measured by monthly phone calls, but
not reported in paper. Likewise, duration
of hospitalisations and sputum bacteriol-
ogy recorded but not reported. Antibiotic
use was partially reported (none received
home IV antibiotics). FEV , FEF25−75%
and Shwachman scores are fully reported
though P values not given and only de-
scribed as non-significant.Huang score was
significantly improved (P = 0.04) in the AD
group versus PD&P group. Baseline FVC
and Huang score recorded but unreported
Other bias Low risk None identified.
Miller 1995
Methods RCT.
Cross-over design: each participant used 2 treatment regimens: AD alone or ACBT with
PD in randomised order over 2 days 1 week apart
Single centre.
Location: UK.
Participants 18 participants withCF, all clinically stable at the time of the study andwere not receiving
IV antibiotics
Age: 11 to 32 years.
Gender split: 10 male, 8 female.
Shwachman-Kulczycki scores modified with the Chrispin-Norman scores: range 34 - 87
Interventions Treatment 1: AD alone for 2 days, each day consisting of 2 identical treatment sessions
(morning and afternoon) with each session lasting 30 minutes
Treatment 2: ACBT with PD for 2 days, each day consisting of 2 identical treatment
sessions (morning and afternoon) with each session lasting 30 minutes
Treatment preceded either by nebulised salbutamol (2.5 mL salbutamol and 1.5 mL
saline) or saline (4 mL), based on reversibility response to bronchodilator. Approximate
nebulisation time of 8 minutes
Participants were asked to be regular with their home physiotherapy in the week leading
up to the study and in the intervening period
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Miller 1995 (Continued)
Outcomes The same measurements were taken on day 1 and day 2.
Lung function tests (FEV , FVC, FEF25−75% and PEF) recorded at the beginning of
the day and before and after each physiotherapy treatment
Oxygen saturation levels measured before, during and after each physiotherapy session
Sputum collected and weighed during treatment and for a further hour after it
Participant preference.
Additional outcome: Xenon-133 gas ventilation study at the start and end of each day
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Eighteen patients with cystic fibrosis took
part in a randomized two-day crossover
trial”. Method of randomisation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
overall. The extent to which the lack of
blinding may have had an effect on the re-
porting of subjective outcomes such as pa-
tient preference is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions, all participants analysed in
the groups to which they were assigned
Selective reporting (reporting bias) Low risk Taken overall, lung function tests were re-
ported, but only FVC and FEF25−75% in
any detail.
Xenon-133 gas ventilation study was re-
ported, as were oxygen saturation levels,
sputum weights and preference of tech-
nique
No baseline or raw data provided.
Conclusions based on the statistical analysis
were summarised
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Miller 1995 (Continued)
Other bias High risk Those on their ACBT day were asked to
breathe normally during their pre-treat-
ment nebuliser. Those on AD, however,
performed AD breathing exercises during
inhalation, adding 8 minutes of “extra”
treatment time. No statistically significant
differences were found between the 2 treat-
ment groups for any of the outcomes mea-
sured. Despite this, the risk of bias was
deemed to be high as the stated treatment
time for the 2 groups was unequal, favour-
ing the AD group
Osman 2010
Methods RCT.
Cross-over design: 4 consecutive study days where participants received either HFCWO
on days 1 and 3 and their “usual” ACT on days 2 and 4 or vice versa.
Single centre.
Location: UK.
Participants 30 participants with a diagnosis of CF based on genotype or sweat test whowere admitted
to hospital with an acute infective pulmonary exacerbation
Age: mean (SD) 29.4 (8.4) years.
Gender split: 22 male, 8 female.
FEV % predicted: mean (SD) 38% (16.7).
Inclusion criteria: FEV ≥ 20% predicted, age ≥ 16 years and have an acute infective
pulmonary exacerbation
Interventions 4 consecutive study days where participants received either HFCWO on days 1 and 3
and their “usual” ACT on days 2 and 4 or vice versa
Treatment 1: 2x daily HFCWO sessions (am and pm) of 30 min each where partici-
pants remained in an upright position throughout the session; 8 minutes at each of the
frequencies in sequence (10, 13 and 15 Hz), with each frequency followed by a 2-minute
rest period. Pulse pressure set according to the individual’s reported comfort. Participants
advised to huff or cough as they felt necessary to expectorate secretions
Treatment 2: 2x daily “usual” ACT sessions (am and pm) of 30 min each. For those
practicing an assisted ACT, the physiotherapist provided percussion (i.e. ACBT with
PD&P), participants were allowed to perform combined ACTs where this was their usual
practice
Outcomes Wet weight of expectorated sputum, FEV , oxygen saturation levels, perceived efficacy
and comfort of each ACT as well as the incidence of urinary leakage during treatment
was measured using a Visual Analogue Scale. ACT preference was documented for each
participant
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Osman 2010 (Continued)
Notes “Usual” ACT incorporated: ACBT with PD&P (41%, n = 12), ACBT with modified
PD alone (7%, n = 2), AD in sitting (28%, n = 8), AD with modified PD (7%, n = 2),
PEP (7%, n = 2), Flutter® (10%, n = 3)
ACTs in the published paper were analysed together and results were not separated out
for the individual techniques
The study authors were contacted and provided us with the raw data for each participant,
including what their usual therapies were and all first-arm data before the first cross-over
on day 1. Only 10 out of the 30 participants in the study performed AD as their usual
ACT. It was felt that analysing these AD participants in a subset would not add relevance
due to the very small numbers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Allocation to HFCWO or usual ACT on
day 1 was determined using a computer-
generated randomisation table.”
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
overall. The extent to which the lack of
blinding may have had an effect on the re-
porting of subjective outcomes such asQoL
measures is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Paper states that “An independent ob-
server, blind to the daily method of airway
clearance used, performed the spirometry,
weighed the sputum samples and collected
the 10 cm VAS throughout the study.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Single withdrawal discussed; participant
excluded due to a hypoglycaemic episode.
Results based on the remaining 29 partici-
pants
Selective reporting (reporting bias) Low risk All outcomes reported; 2 out of 116 24-
hour sputum samples were discarded as
they were incomplete
Powered to detect a 4 g difference in expec-
torated sputum.
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Osman 2010 (Continued)
Other bias Unclear risk Supported by the Robert Luff Foundation
andHill Rom Inc. AlthoughHill Rom pro-
vided some equipment for the study, they
did not participate in the design, collec-
tion, analysis, interpretation of data or in
the writing of the manuscript
Pfleger 1992
Methods RCT.
Cross-over design: in a random order, participants performed a different regimen of
physiotherapy over 5 consecutive outpatient visits
Single centre.
Location: Austria.
Participants 15 participants with CF, diagnosis confirmed by “repeatedly positive sweat tests”. All
participants in a “stable clinical situation”. All participants trained to cooperate with
pulmonary function testing (6 months prior to the study, each participant trained in 2
self-administered techniques (Hi-PEP mask (PEP) and AD) and encouraged to use these
2 techniques daily until the onset of the study), able to perform chest physiotherapy 1
to 3 times daily and produce > 20 mL sputum per day. One participant excluded due to
an acute respiratory viral infection. The remaining 14 participants were analysed
Age: > 6 years. Mean (range) age 16.0 (9.8 - 22.4) years.
Gender split: 5 male, 9 female.
Shwachmann score mean (range): 62.2 (26 - 90).
Chest X-ray score mean (range): 13.8 (6 - 20).
Interventions Treatment time individualised and performed 1x daily. Each treatment session was equal
to the time taken for the individual to clear the lungs using AD, as judged from pre-
study experience
Regimen 1: Hi-PEP mask alone (PEP).
Regimen 2: AD alone (AD).
Regimen 3: Hi-PEP mask for the first half of the session, followed by AD (PEP-AD)
Regimen 4: AD for the first half of the session, followed by Hi-PEP mask (AD-PEP)
Regimen 5: control (spontaneous coughing only).
Outcomes FEV and FVC measured at all PFT measurement points. Total sputum weight (not
stated whether wet or dry) during the complete treatment session also measured
Notes One participant excluded from the study due to an acute respiratory viral infection
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Participants were “randomly selected from
the patients of the local CF clinic”. No fur-
ther details
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Sputum was collected by the participants
and weighed by an investigator blinded to
the method of physiotherapy used. Does
not state whether the statisticians or those
carrying out the PFTs were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Single withdrawal discussed; participant
excluded due to an acute respiratory viral
infection. Results based on remaining 14
participants
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Treatment time individualised and the au-
thors state that each treatment session was
equal to the time taken for the individ-
ual to clear the lungs using AD, as judged
from pre-study experience. This would im-
ply that duration of each of the 5 treat-
ment sessions performed by an individual
should be the same. Additionally, its dura-
tion would have been decided in advance
and ought to remain unchanged over the
course of the study. Nonetheless, the au-
thors report that the “time needed to clear
the lungs...for PEP, however, was shorter
than for the other forms of physiotherapy
and this difference reached statistical sig-
nificance for AD (P < 0.05), PEP-AD (P
< 0.02), and AD-PEP (P < 0.05)”. In this
case, the results reported are not consistent
with the methods described
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Pryor 2010
Methods RCT.
Parallel design.
Single centre.
Location: UK.
Participants 75 participants with “proven diagnosis” of CF (genotype and positive sweat test); 15
participants randomised to each of 5 intervention groups
Age: 16 years or older; range 17 - 63 years.
Gender split: 47 males, 28 females.
FEV : ≥ 25% predicted.
Exclusion criteria: evidence of a current respiratory exacerbation, past history of pneu-
mothorax, current severe haemoptysis, awaiting lung and heart or lung transplantation,
pregnancy and recent (within 3 months) acquisition of Burkholderia cepacia.
Interventions The number of sessions per day and the length of time for treatment was individualised
in agreement with each participant, written instructions of the regimens agreed were
given to each participant
Regimen 1: AD.
Regimen 2: ACBT.
Regimen 3: Cornet®.
Regimen 4: Flutter®.
Regimen 5: PEP.
Outcomes Primary outcome: FEV .
Secondary outcomes: FVC, BMI, the modified shuttle test, number of courses of IV
antibiotics and the Short Form-36 and Chronic Respiratory Questionnaires
MEF25 and residual volume as a percent of total lung capacity were reported in the study,
but are not included in our analysis as they were not outcomes relevant to our review
Participants requested to attend monthly for 12 months, for a review of their ACT and
to record the outcome measurements. The measurements of lung function and BMI
were undertaken at 0, 6 and 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas computerised and used
a random number sequence stratified by
FEV % predicted (FEV < 50%; FEV
≥ 50%) and sputum expectorated (< 1
cupful per day;≥ 1 cupful per day). Partic-
ipants randomized to 1 of the 5 regimens
of ACBT, AD, Cornet®, Flutter® or PEP
Allocation concealment (selection bias) Unclear risk Not stated.
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Pryor 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither participants nor physiotherapy
personnel were blinded to the self-ad-
ministered physiotherapy techniques un-
der study. As it is not possible to blind by
design, the risk of bias is deemed to be low
overall. The extent to which the lack of
blinding may have had an effect on the re-
porting of subjective outcomes such asQoL
measures is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The measurements of lung function and
BMI and the statistical analysis were under-
taken by observers (physiologists and statis-
tician) blind to the regimen to which the
participants had been randomised
Incomplete outcome data (attrition bias)
All outcomes
Low risk 75 entered the study, but only data on 65
available at 12 months (13.3 % excluded) -
“Intention to treat was used for the primary
outcome of FEV ”
53 stayed in the group to which they were
randomised.
22didnot complete the study - reasons pro-
vided but not according to specific group
allocation
Selective reporting (reporting bias) High risk FEV is the only outcome reported in de-
tail. However, there is no report of the 6-
month data taken for lung function or BMI
FVC, BMI and exercise capacity report no
significant difference and P values at 12
months
Some participants in each of the regimens
required IV antibiotics, median number of
courses per group 1.0 to 1.5, but these data
were not analysed in the study due to small
numbers and scattered nature of the data
QoL data reported.
Other bias Unclear risk Treatment used prior to baseline was not
reported, which will have had an impact
on the capacity of the individual to engage
with a new technique
ABPA: allergic bronchopulmonary aspergillosis
ACT: airway clearance technique
ACBT: active cycle of breathing technique
AD: autogenic drainage
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BMI: body mass index
CF: cystic fibrosis
FEF25−75%: forced mid-expiratory flow between 25% and 75% of forced vital capacity
FET: forced expiration technique
FEV : forced expiratory volume at one second
FVC: forced vital capacity
HFCWO: high frequency chest wall oscillation
IPV: intrapulmonary percussive ventilation
IV: intravenous
MEF25%: maximal expiratory flow at 25% of forced vital capacity
PD: postural drainage
PD&P: postural drainage and percussion
PEP: positive expiratory pressure
PFT: pulmonary function test
QoL: quality of life
RCT: randomised controlled trial
VAS: visual analogue score
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Giles 1995 Single treatment session with AD.
Herrero 2016 Single treatment session with AD.
Lindemann 1992 Single treatment session with AD.
NCT01885650 AD used in both treatment groups; study comparing NIV with no NIV
NCT02303808 AD used in both treatment groups; study comparing inhalation with and without PEP
Reix 2012 After careful appraisal of the methodology of the paper it was considered that exercise and expiratory
manoeuvres were being compared to a modified ACBT, and not an AD technique
Roos 1987 Study was not completed when abstract was published. Further information was unattainable from the
authors after this length of time
Skopnik 1986 No evidence of randomisation in this study. Ventilation scintigraphy was the only outcome measure and
this is not an outcome under evaluation in this review
van Ginderdeuren 2001 This study describes assisted AD in infants which is a different technique and not under review
van Ginderdeuren 2008 The intervention under review in this study was not AD but a comparison of two different inhalation
regimes prior to AD (i.e. saline alone or saline accompanied by IPV)
van Ginderdeuren 2011 AD is not compared to any other ACT. The variable is the time of administration of the hypertonic saline
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(Continued)
Warwick 1990 Intervention not appropriate for this review. Manual chest physiotherapy was compared to the Thairapy®
bronchial drainage vest
ACBT; active cycle of breathing technique
ACT: airway clearance technique
AD: autogenic drainage
IPV: intrapulmonary percussive ventilation
NIV: non-invasive ventilation
PEP: positive expiratory pressure
Characteristics of studies awaiting assessment [ordered by study ID]
Davies 2012
Methods RCT.
Parallel design.
Single centre.
Location: UK.
Participants Inclusion criteria:
• diagnosis of CF;
• hospitalised patients admitted with a pulmonary infection;
• FEV
of 15% predicted or over;
• 16 years of age or over.
Exclusion criteria:
• current severe haemoptysis;
• rib fractures or history of spontaneous rib fractures;
• pregnancy;
• lung abscess;
• end-stage disease;
• requiring more than 2 assisted treatment sessions per day;
• requiring treatment with positive pressure;
• inability to give consent.
Interventions Treatment 1: usual ACT - 2 self-administered treatment sessions a day and 2 treatments a day assisted by a physio-
therapist (both using the participant’s usual ACT (ACBT, AD, PEP, manual techniques or oscillating PEP)
Treatment 2: HFCWO - 2 self-administered treatments a day using HFCWO and 2 treatment sessions a day assisted
by a physiotherapist using their usual ACT
Outcomes Primary outcome measures: mean % change in FEV .
Secondary outcome measures: wet weight of sputum expectorated in 24 hours, length of time to next course of
intravenous antibiotics, rate of change of C-reactive protein
Notes
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Vendrusculo 2017
Methods Prospective randomised controlled pilot study of cross-over design (two tests with one month washout in between)
Participants Eligible participants: children with CF aged over 9 years and who were over 128 cm in height. Participants excluded
if they were chronically infected with Burkholderia cepacia and non-tuberculous Mycobacterium abscessus.
n = 12
Age, mean (SD): 12.83 (1.85) years.
Gender split: 6 boys, 6 girls.
FEV z score, mean (SD): -0.51 (0.76).
FVC z score, mean (SD): -0.17 (0.97).
Interventions Group 1: cardiopulmonary exercise testing with usual ACT (PEP and AD)
Group 2: cardiopulmonary exercise testing alone.
Outcomes Peak VO , VE , VEVO , VEVCO
Notes
ACBT: active cycle of breathing techniques
ACT: airway clearance technique
AD: autogenic drainage
CF: cystic fibrosis
FEV : forced expiratory volume in one second
FVC: forced vital capacity
HFCWO: high frequency chest wall oscillation
PEP: positive expiratory pressure
RCT: randomised controlled trial
VE : minute ventilation
VEVCO : ventilation relative to carbon dioxide production
VEVO : ventilation relative to oxygen consumption
VO : oxygen consumption
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D A T A A N D A N A L Y S E S
Comparison 1. AD versus PD&P
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (change in % predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 at 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Hospital admissions 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 at 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 FVC (change in % predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 at 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEF25-75% (change in %
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 at 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. AD versus spontaneous cough
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 30 minutes following
physiotherapy
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 30 minutes following
physiotherapy
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Sputum weight (g) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 30 minutes following
physiotherapy
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. AD versus ACBT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. AD versus PEP
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FEV (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 30 minutes following
physiotherapy
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 FVC (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 30 minutes following
physiotherapy
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sputum weight (g) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Following physiotherapy 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. AD versus Cornet®
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. AD versus Flutter®
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV (L) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Sputum volume wet (g) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 At 1 month 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 AD versus PD&P, Outcome 1 FEV (change in % predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 1 AD versus PD%P
Outcome: 1 FEV (change in % predicted)
Study or subgroup AD PD % P
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 12 months
McIlwaine 2010 17 0.97 (2.25) 16 2.09 (2.2) -1.12 [ -2.64, 0.40 ]
-2 -1 0 1 2
Favours PD % P Favours AD
Analysis 1.2. Comparison 1 AD versus PD&P, Outcome 2 Hospital admissions.
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 1 AD versus PD%P
Outcome: 2 Hospital admissions
Study or subgroup AD PD%P
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 12 months
McIlwaine 2010 17 0.76 (0.18) 16 1 (0.32) -0.24 [ -0.42, -0.06 ]
-1 -0.5 0 0.5 1
Favours AD Favours PD%P
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Analysis 1.3. Comparison 1 AD versus PD&P, Outcome 3 FVC (change in % predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 1 AD versus PD%P
Outcome: 3 FVC (change in % predicted)
Study or subgroup AD PD%P
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 12 months
McIlwaine 2010 17 2.35 (1.87) 16 0.47 (1.65) 1.88 [ 0.68, 3.08 ]
-4 -2 0 2 4
Favours PD%P Favours AD
Analysis 1.4. Comparison 1 AD versus PD&P, Outcome 4 FEF25-75% (change in % predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 1 AD versus PD%P
Outcome: 4 FEF25−75% (change in % predicted)
Study or subgroup AD PD%P
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 12 months
McIlwaine 2010 17 -1.91 (3.75) 16 5.63 (4.55) -7.54 [ -10.39, -4.69 ]
-20 -10 0 10 20
Favours PD%P Favours AD
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Analysis 2.1. Comparison 2 AD versus spontaneous cough, Outcome 1 FEV (% predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 2 AD versus spontaneous cough
Outcome: 1 FEV (% predicted)
Study or subgroup AD Spontaneous cough
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 30 minutes following physiotherapy
Pfleger 1992 14 56 (19) 14 53 (19) 3.00 [ -11.08, 17.08 ]
-100 -50 0 50 100
Favours spontaneous cough Favours AD
Analysis 2.2. Comparison 2 AD versus spontaneous cough, Outcome 2 FVC (% predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 2 AD versus spontaneous cough
Outcome: 2 FVC (% predicted)
Study or subgroup AD Spontaneous cough
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 30 minutes following physiotherapy
Pfleger 1992 14 74 (19) 14 70 (21) 4.00 [ -10.83, 18.83 ]
-100 -50 0 50 100
Favours spontaneous cough Favours AD
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Analysis 2.3. Comparison 2 AD versus spontaneous cough, Outcome 3 Sputum weight (g).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 2 AD versus spontaneous cough
Outcome: 3 Sputum weight (g)
Study or subgroup AD Spontaneous cough
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 30 minutes following physiotherapy
Pfleger 1992 14 35 (25.83) 14 16.67 (13.3) 18.33 [ 3.11, 33.55 ]
-100 -50 0 50 100
Favours spontaneous cough Favours AD
Analysis 3.1. Comparison 3 AD versus ACBT, Outcome 1 FEV (L).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 3 AD versus ACBT
Outcome: 1 FEV (L)
Study or subgroup AD ACBT
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 months
Pryor 2010 13 2.64 (1.22) 13 1.94 (0.8) 0.70 [ -0.09, 1.49 ]
-2 -1 0 1 2
Favours ACBT Favours AD
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Analysis 4.1. Comparison 4 AD versus PEP, Outcome 1 FEV (L).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 4 AD versus PEP
Outcome: 1 FEV (L)
Study or subgroup AD PEP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 months
Pryor 2010 13 2.64 (1.22) 13 2.02 (1.17) 0.62 [ -0.30, 1.54 ]
-2 -1 0 1 2
Favours PEP Favours AD
Analysis 4.2. Comparison 4 AD versus PEP, Outcome 2 FEV (% predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 4 AD versus PEP
Outcome: 2 FEV (% predicted)
Study or subgroup AD PEP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 30 minutes following physiotherapy
Pfleger 1992 14 56 (19) 14 54 (20) 2.00 [ -12.45, 16.45 ]
-100 -50 0 50 100
Favours PEP Favours AD
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Analysis 4.3. Comparison 4 AD versus PEP, Outcome 3 FVC (% predicted).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 4 AD versus PEP
Outcome: 3 FVC (% predicted)
Study or subgroup AD PEP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 30 minutes following physiotherapy
Pfleger 1992 14 74 (19) 14 73 (20) 1.00 [ -13.45, 15.45 ]
-20 -10 0 10 20
Favours PEP Favours AD
Analysis 4.4. Comparison 4 AD versus PEP, Outcome 4 Sputum weight (g).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 4 AD versus PEP
Outcome: 4 Sputum weight (g)
Study or subgroup AD PEP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Following physiotherapy
Pfleger 1992 14 35 (25) 14 50 (30) -15.00 [ -35.46, 5.46 ]
-1000 -500 0 500 1000
Favours PEP Favours AD
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Analysis 5.1. Comparison 5 AD versus Cornet®, Outcome 1 FEV (L).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 5 AD versus Cornet
Outcome: 1 FEV (L)
Study or subgroup AD Cornet
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 12 months
Pryor 2010 13 2.64 (1.22) 14 1.9 (0.89) 0.74 [ -0.07, 1.55 ]
-2 -1 0 1 2
Favours Cornet Favours AD
Analysis 6.1. Comparison 6 AD versus Flutter®, Outcome 1 FEV (L).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 6 AD versus Flutter
Outcome: 1 FEV (L)
Study or subgroup AD Flutter
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
App 1998 7 2.1 (1.1) 7 2 (0.9) 0.10 [ -0.95, 1.15 ]
2 At 12 months
Pryor 2010 13 2.64 (1.22) 12 2.43 (0.94) 0.21 [ -0.64, 1.06 ]
-1 -0.5 0 0.5 1
Favours Flutter Favours AD
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Analysis 6.2. Comparison 6 AD versus Flutter®, Outcome 2 FVC (L).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 6 AD versus Flutter
Outcome: 2 FVC (L)
Study or subgroup AD Flutter
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
App 1998 7 2.9 (1.5) 7 3.2 (0.6) -0.30 [ -1.50, 0.90 ]
-2 -1 0 1 2
Favours Flutter Favours AD
Analysis 6.3. Comparison 6 AD versus Flutter®, Outcome 3 Sputum volume wet (g).
Review: Autogenic drainage for airway clearance in cystic fibrosis
Comparison: 6 AD versus Flutter
Outcome: 3 Sputum volume wet (g)
Study or subgroup AD Flutter
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
App 1998 7 3.6 (2.5) 7 4.5 (2.5) -0.90 [ -3.52, 1.72 ]
-4 -2 0 2 4
Favours Flutter Favours AD
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Post hoc changes for initial review version
Outcome measures
1. In the protocol, sputum weight was included as a primary outcome measure. For the review we downgraded sputum weight to a
secondary measure and we promoted quality of life (QoL) assessment to a primary outcome. Reasons for this change were:
• to better reflect the improving condition of people with cystic fibrosis (CF);
• to reflect concerns over the validity and reliability of sputum weight collection as a primary outcome; and
• to implement advice following discussion with other members of the Cochrane Review Group, including editors of
physiotherapy reviews.
By making this change we feel the review better reflects outcomes that are meaningful to people with CF, although we appreciate that
for more severely affected individuals sputum weight may be relevant and we keep this as an important secondary outcome.
2. We have included lung clearance index into the secondary outcomes as a post hoc change. It is an emerging outcome measure with
increasing validity, which may provide a more sensitive assessment of change in respiratory function.
3. The secondary outcomes have also been re-ordered so that they are listed in order of importance in the view of the new author team.
Inclusion criteria
The new authors also did not accept that single intervention episodes were appropriate for this technique and therefore excluded any
studies that lasted for only a single episode.
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Reporting data
When reporting short-term studies (up to one month), the new authors reported outcomes of up to seven days, and from one to four
weeks. Likewise, the outcome data for longer-term studies were reported as those measured at one month, three months, six months,
12 months and annually thereafter.
Summary of findings table
A summary of findings table for each comparison of the review was added as a post hoc change. Outcomes presented in these tables
were presented based on clinical relevance rather than those which contributed the most data.
N O T E S
A new author team took on this review after the protocol had been published.
76Autogenic drainage for airway clearance in cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
